SCHEDULE 14A INFORMATION
Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934
(Amendment No. )

Filed by the Registrant [X]
Filed by a Party other than the Registrant [ ]

Check the appropriate box:

[ ] Preliminary Proxy Statement

[ ] Confidential, for Use of the Commission Only (as permitted by
Rule 14a-6(e)(2))

[X] Definitive Proxy Statement

[ ] Definitive Additional Materials

[ ] Soliciting Material Pursuant to ss.Section 240.14a-11(c) or ss.Section 240.14a-12

Molecular Devices Corporation
- --------------------------------------------------------------------------------
(Name of Registrant as Specified In Its Charter)

- --------------------------------------------------------------------------------
(Name of Person(s) Filing Proxy Statement if Other Than the Registrant)

Payment of Filing Fee (Check the appropriate box)

[X] No fee required.
[ ] Fee computed on table below per Exchange Act Rules 14a-6(i)(4) and 0-11.

1. Title of each class of securities to which transaction applies:

- --------------------------------------------------------------------------------

2. Aggregate number of securities to which transaction applies:

- --------------------------------------------------------------------------------

3. Per unit price or other underlying value of transaction computed pursuant to
Exchange Act Rule 0-11 (Set forth the amount on which the filing fee is
calculated and state how it was determined):

- --------------------------------------------------------------------------------

4. Proposed maximum aggregate value of transaction:

- --------------------------------------------------------------------------------

5. Total fee paid:

- --------------------------------------------------------------------------------

[ ] Fee paid previously with preliminary materials.

[ ] Check box if any part of the fee is offset as provided by Exchange Act Rule
0-11(a)(2) and identify the filing for which the offsetting fee was paid
previously. Identify the previous filing by registration statement number,
or the Form or Schedule and the date of its filing.

6. Amount Previously Paid:

- --------------------------------------------------------------------------------

7. Form, Schedule or Registration Statement No.:

Definitive 14A
- --------------------------------------------------------------------------------

8. Filing Party:

Molecular Devices Corporation
- --------------------------------------------------------------------------------

9. Date Filed:

April 25, 2000
- --------------------------------------------------------------------------------

MOLECULAR DEVICES CORPORATION
1311 Orleans Drive
Sunnyvale, CaliforniaORLEANS DRIVE
SUNNYVALE, CA 94089
------------------------

NOTICE OF ANNUAL MEETING OF STOCKHOLDERS
TO BE HELD ON MAY 20, 199925, 2000

TO THE STOCKHOLDERS OF MOLECULAR DEVICES CORPORATION:

NOTICE IS HEREBY GIVEN that the Annual Meeting of Stockholders of MOLECULAR DEVICES CORPORATION,Molecular
Devices Corporation, a Delaware corporation (the "Company"), will be held on
Thursday, May 20, 199925, 2000 at 10:30 a.m. local time at the Company's corporate
headquarters, located at 1311 Orleans Drive, Sunnyvale, California 94089 for the
following purpose:purposes:

1. To elect directors to serve for the ensuing year and until their
successors are elected.

2. To approve amendments to the Company's 1995 Stock Option Plan (i) to
increase the aggregate number of shares of Common Stock authorized for
issuance under such plan by 1,000,000 shares, and (ii) to make certain
technical amendments to the plan.

3. To approve amendments to the Company's 1995 Non-Employee Directors'
Stock Option Plan (i) to increase the aggregate number of shares of
Common Stock authorized for issuance under such plan by 100,000 shares,
(ii) to revise the timing, vesting and number of shares subject to
grants to be issued to non-employee directors, and (iii) to make
certain technical amendments to the plan.

4. To ratify the selection of Ernst & Young LLP as independent auditors of
the Company for its fiscal year ending December 31, 1999.

5.2000.

3. To transact such other business as may properly come before the meeting
or any adjournment or postponement thereof.

The foregoing items of business are more fully described in the Proxy
Statement accompanying this Notice.

The Board of Directors has fixed the close of business on March 26,
1999,27, 2000,
as the record date for the determination of stockholders entitled to notice of
and to vote at this Annual Meeting and at any adjournment or postponement
thereof.

By Order of the Board of Directors

/s/ Andrei M. Manoliu

Andrei M. ManoliuJAMES C. KITCH

James C. Kitch
Secretary

Sunnyvale, California
April 16, 1999

All Stockholders are cordially invited to attend the meeting in person.
Whether or not you expect to attend the meeting, please complete, date, sign and
return the enclosed proxy as promptly as possible in order to ensure your
representation at the meeting.26, 2000

ALL STOCKHOLDERS ARE CORDIALLY INVITED TO ATTEND THE MEETING IN PERSON.
WHETHER OR NOT YOU EXPECT TO ATTEND THE MEETING, PLEASE COMPLETE, DATE, SIGN AND
RETURN THE ENCLOSED PROXY AS PROMPTLY AS POSSIBLE IN ORDER TO ENSURE YOUR
REPRESENTATION AT THE MEETING. A return envelope (which is postage prepaid if
mailed in the United States) is enclosed for that purpose. Even if you have
given your proxy, you may still vote in person if you attend the meeting. Please
note, however, that if your shares are held of record by a broker, bank or other
nominee and you wish to vote at the meeting, you must obtain from the record
holder a proxy issued in your name.RETURN ENVELOPE (WHICH IS POSTAGE PREPAID IF
MAILED IN THE UNITED STATES) IS ENCLOSED FOR THAT PURPOSE. EVEN IF YOU HAVE
GIVEN YOUR PROXY, YOU MAY STILL VOTE IN PERSON IF YOU ATTEND THE MEETING. PLEASE
NOTE, HOWEVER, THAT IF YOUR SHARES ARE HELD OF RECORD BY A BROKER, BANK OR OTHER
NOMINEE AND YOU WISH TO VOTE AT THE MEETING, YOU MUST OBTAIN FROM THE RECORD
HOLDER A PROXY ISSUED IN YOUR NAME.
3

MOLECULAR DEVICES CORPORATION
1311 Orleans Drive
Sunnyvale, CaliforniaORLEANS DRIVE
SUNNYVALE, CALIFORNIA 94089
------------------------

PROXY STATEMENT
FOR ANNUAL MEETING OF STOCKHOLDERS
May 20, 1999MAY 25, 2000
------------------------

INFORMATION CONCERNING SOLICITATION AND VOTING

GENERAL

The enclosed proxy is solicited on behalf of the Board of Directors of
Molecular Devices Corporation, a Delaware corporation (the("Molecular Devices" or
the "Company"), for use at the Annual Meeting of Stockholders to be held on May
20, 1999,25, 2000, at 10:30 a.m. local time (the "Annual Meeting"), or at any adjournment
or postponement thereof, for the purposes set forth herein and in the
accompanying Notice of Annual Meeting. The Annual Meeting will be held at the
Company's corporate headquarters, located at 1311 Orleans Drive, Sunnyvale,
California 94089. The Company intends to mail this proxy statement and
accompanying proxy card on or about April 16,
1999,26, 2000, to all stockholders entitled
to vote at the Annual Meeting.

SOLICITATION

The Company will bear the entire cost of solicitation of proxies, including
preparation, assembly, printing and mailing of this proxy statement, the proxy
card and any additional information furnished to stockholders. Copies of
solicitation materials will be furnished to banks, brokerage houses, fiduciaries
and custodians holding in their names shares of Common Stock beneficially owned
by others to forward to such beneficial owners. The Company may reimburse
persons representing beneficial owners of Common Stock for their costs of
forwarding solicitation materials to such beneficial owners. Original
solicitation of proxies by mail may be supplemented by telephone, telegram or
personal solicitation by directors, officers or other regular employees of the
Company. No additional compensation will be paid to directors, officers or other
regular employees for such services.

VOTING RIGHTS AND OUTSTANDING SHARES

Only holders of record of Common Stock at the close of business on March
26, 199927, 2000 will be entitled to notice of and to vote at the Annual Meeting. At the
close of business on March 26, 199927, 2000 the Company had outstanding and entitled to
vote 9,543,4899,741,501 shares of Common Stock.

Each holder of record of Common Stock on such date will be entitled to one
vote for each share held on all matters to be voted upon at the Annual Meeting.

All votes will be tabulated by the inspector of election appointed for the
meeting, who will separately tabulate affirmative and negative votes,
abstentions and broker non-votes. Abstentions will be counted towards the
tabulation of votes cast on proposals presented to the stockholders and will
have the same effect as negative votes. Broker non-votes are counted towards a
quorum, but are not counted for any purpose in determining whether a matter has
been approved.

REVOCABILITY OF PROXIES

Any person giving a proxy pursuant to this solicitation has the power to
revoke it at any time before it is voted. It may be revoked by filing with the
Secretary of the Company at the Company's principal executive office, 1311
Orleans Drive, Sunnyvale, California 94089, a written notice of revocation or a
duly executed proxy bearing a later date, or it may be revoked by attending the
meeting and voting in person. Attendance at the meeting will not, by itself,
revoke a proxy.
4

STOCKHOLDER PROPOSALS

The deadline for submitting a stockholder proposal for inclusion in the
Company's proxy statement and form of proxy for the Company's 20002001 annual
meeting of stockholders pursuant to Rule 14a-8 of the Securities and Exchange
Commission is December 11, 1999.21, 2000. The deadline for submitting a stockholder
proposal or a nomination for director that is not to be included in such proxy
statement and proxy is February 9, 2000.19, 2001. Such proposal or nomination, however,
may not be submitted before January 10, 2000.20, 2001. Stockholders are also advised to
review the Company's By-laws, which contain additional requirements with respect
to advance notice of stockholder proposals and director nominations.

PROPOSAL 1

ELECTION OF DIRECTORS

There are eight nominees for the eight Board positions presently authorized
in the Company's By-laws. Each director to be elected will hold office until the
next annual meeting of stockholders and until his successor is elected and has
qualified, or until such director's earlier death, resignation or removal. Each
nominee listed below is currently a director of the Company, all eight directors
having been elected by the stockholders.

Directors are elected by a plurality of the votes present in person or
represented by proxy and entitled to vote. Shares represented by executed
proxies will be voted, if authority to do so is not withheld, for the election
of the eight nominees named below. In the event that any nominee should be
unavailable for election as a result of an unexpected occurrence, such shares
will be voted for the election of such substitute nominee as management may
propose. Each person nominated for election has agreed to serve if elected and
management has no reason to believe that any nominee will be unable to serve.

Directors are elected by a plurality of the
votes present in person or represented by proxy and entitled to vote.

THE BOARD OF DIRECTORS RECOMMENDS A VOTE IN FAVOR OF EACH NAMED NOMINEE.

NOMINEES

The names of the nominees and certain information about them are set forth
below:

NAME AGE PRINCIPAL OCCUPATION/
NAME AGE POSITION HELD WITH THE COMPANY
---- --- ---------------------------------------------------

Joseph D. Keegan, Ph.D. 45Ph.D............... 46 President, Chief Executive Officer
Moshe H. Alafi 70Alafi....................... 71 General Partner, Alafi Capital Company
David L. Anderson 55Anderson.................... 56 General Partner, Sutter Hill Ventures
A. Blaine Bowman 52Bowman..................... 53 President, Chief Executive Officer, Dionex Corporation
Paul Goddard, Ph.D. 49Ph.D................... 50 President and Chief Executive Officer, Elan
Pharmaceuticals
Andre F. Marion 63Marion...................... 64 Independent Investor
Harden M. McConnell, Ph.D. 71Ph.D............ 72 Robert Eckles Swain Professor of Physical Chemistry at
Stanford University, Management Consultant
J. Allan Waitz, Ph.D. 63Ph.D................. 64 Independent Investor

Joseph D. Keegan, Ph.D., was appointed as President and Chief Executive
Officer of the Company effective March 30, 1998. From 1992 to 1998, Dr. Keegan
served in various positions at Becton Dickinson and Company, a research and
diagnostic company, including the positions of Vice President, Sales and
Service, Vice President, General Manager of the Immunocytometry Systems Division
and, most recently, President of the Worldwide Tissue Culture 2.

Business. From
1987 to 1992, he was employed by LEICA, Inc., a microscope manufacturer, where
he held various senior management positions. Dr. Keegan holds a Ph.D. in
Chemistry from Stanford University.

Moshe H. Alafi has been a director of the Company since 1985. Mr. Alafi has
been the general partner of Alafi Capital Company which specializes in
forming new companies in the medical, pharmaceutical and biological fields,
since January 1984.

2
5

David L. Anderson has been a director of the Company since 1983. Mr.
Anderson has been a managing director of the general partner of Sutter Hill
Ventures, a California
limited partnership, a venture capital investment partnership,firm, since 1974. Mr. Anderson is also a director of
Cytel Corp., a biotechnology company, Dionex Corporation a leading supplier of analytical instrumentation ("Dionex")(Dionex), Broadvision and Broadvision, Inc., a software company.several private corporations.

A. Blaine Bowman has been a director of the Company since 1985. Mr. Bowman
is, and has been since 1980, President, Chief Executive Officer and a director
of Dionex.

Paul Goddard, Ph.D., has been a director of the Company since September
1995. Dr. Goddard has served as President and Chief Executive Officer of Elan
Pharmaceuticals, a division of Elan PLC, since 1998. Dr. Goddard served as
Chairman, Chief Executive Officer and Director of Neurex Corporation from 1991
through 1998 when Neurex Corporation was acquired by Elan PLC. From 1976 through
February 1991, Dr. Goddard was employed by SmithKline Beecham Corp., a
pharmaceutical company, and its
predecessors in various positions, most recently as Senior Vice President and
Director, Japan-Pacific. He is also a director of Onyx Pharmaceutical Inc. and
was a director of RibiImmunochem Research Inc.until October 1999.

Andre F. Marion has been a director of the Company since September 1995.
Mr. Marion was a founder of Applied Biosystems, Inc., a supplier of
instruments for biotechnology research, and served as its Chief
Operating Officer from 1983 to 1986, its President from 1985 to 1993, its Chief
Executive Officer from 1986 to 1993 and its Chairman of the Board from 1987 to
February 1993, when it merged with the Perkin-Elmer Corporation, a manufacturer of
analytical instruments.Corporation. Mr. Marion
served as Vice President of Perkin-Elmer Corporation and President of its
Applied Biosystems Division until his retirement in February 1995. Mr. Marion is
presently a management consultant and also a director of Applied Imaging Corp.,
a manufacturer of medical computer
systems, and Cygnus, Inc., a developer of drug deliveryAclara Biosciences, Inc. and diagnostic systems.several private corporations.

Harden M. McConnell, Ph.D., founder of the Company, has been a director of
and a consultant to the Company since the Company's inception in July 1983. He
is the Robert Eckles Swain Professor of Physical Chemistry at Stanford
University and a member of the National Academy of Sciences. Dr. McConnell has
received many awards in recognition of his scientific work, most recently these
include the 1987 Pauling Medal for Chemistry and, in 1988, the National Academy
of Sciences Award in Chemical Sciences. Dr. McConnell has also received the Wolf
Prize (1984), the Wheland Medal (1988), the National Medal of Science (1989),
the Peter Debeye Award in Physical Chemistry (1990) and the Bruker Prize of the
Royal Society of Chemistry (1995). Dr. McConnell holds a Ph.D. degree from the
California Institute of Technology.

J. Allan Waitz, Ph.D., has been a director of the Company since 1990. Dr.
Waitz is currently retired. Until 1992, Dr. Waitz was President and Chief
Executive Officer of DNAX Research Institute of Molecular and Cellular Biology,
Inc., a subsidiary of Schering-Plough Corporation, a pharmaceutical company.Corporation. From 1991 through December
1996, Dr. Waitz served as chairperson of the Area Committee on Microbiology of
the National Committee for Clinical Laboratory Standards. He is also a director
of TerraGen Diversity, Inc.

of Vancouver, BC.

BOARD COMMITTEES AND MEETINGS

During the fiscal year ended December 31, 1998,1999, the Board of Directors held
foursix meetings. The Board of Directors has an Audit Committee and a Compensation
Committee. The Company does not have a nominating committee.

The Audit Committee recommends engagement of the Company's independent
accountants,auditors, approves services performed by such accountants,auditors, and reviews and
evaluates the Company's accounting system and its system of internal

accounting
controls. The Audit Committee is composed of three non-employee directors: Dr.
McConnell, Dr. Goddard and Mr. Bowman. It met one time during the fiscal year
ended December 31, 1998.1999.

The Compensation Committee makes recommendations to the Board concerning
cash and long-term incentive compensation for employees of the Company. The
Compensation Committee also makes recommendations to the Board regarding the
number of shares that should be subject to options, the timing of grants of
options under the Company's 1995 Stock Option Plan and the number of shares and
the timing of offerings of such shares to employees under the Company's 1995
Employee Stock Purchase Plan. The Compensation

3
6

Committee is composed of three non-employee directors: Mr. Anderson, Mr. Marion
and Dr. Waitz. It met threetwo times during such fiscal year.

During the fiscal year ended December 31, 1998, each Board member1999, all directors except Dr.
Goddard, Mr. Bowman and Mr. Alafi attended 75% or more of the aggregate of the
meetings of the Board and of the committees on which hethey served, held during
the period for which he wasthey were a director or committee member, respectively.

PROPOSAL 2

APPROVAL OF AMENDMENTS TO THE 1995 STOCK OPTION PLAN

In October 1995, the Board of Directors of the Company (the "Board")
adopted, and the stockholders subsequently approved, the Company's 1995 Stock
Option Plan (the "Option Plan") covering 1,750,000 shares of the Company's
Common Stock. As of January 31, 1999, options (net of canceled or expired
options) covering an aggregate of 885,483 shares of the Company's Common Stock
had been granted and were outstanding under the Option Plan, and only 212,935
shares of Common Stock (plus any shares that might in the future be returned to
the Option Plan as a result of cancellations or expiration of options or the
reacquisition by the Company of issued shares) remained available for future
grant under the Option Plan.

In January 1999, the Board amended the Option Plan, subject to
stockholder approval, to increase the number of shares of Common Stock
authorized for issuance under the Option Plan by 1,000,000 shares. The Board
adopted this amendment in order to ensure that the Company can continue to grant
stock options at levels determined appropriate by the Board. In January 1999,
the Board also amended the Option Plan, subject to stockholder approval to make
certain technical amendments to the plan. The Board adopted this amendment in
order to conform the Option Plan to current provisions of Rule 16b-3 under the
Securities Exchange Act of 1934, and to eliminate provisions applicable prior to
the time the Company became a publicly traded company.

Stockholders are requested in this Proposal 2 to approve the Option
Plan, as amended. The affirmative vote of the holders of a majority of the
shares present in person or represented by proxy and entitled to vote at the
meeting will be required to approve the amendments to the Option Plan.
Abstentions will be counted toward the tabulation of votes cast on proposals
presented to the stockholders and will have the same effect as negative votes.
Broker non-votes are counted towards a quorum, but are not counted for any
purpose in determining whether this matter has been approved.

THE BOARD OF DIRECTORS RECOMMENDS
A VOTE IN FAVOR OF PROPOSAL 2.

The essential features of the Option Plan are outlined below:

GENERAL

The Option Plan provides for the grant of both incentive and
nonstatutory stock options. Incentive stock options granted under the Option
Plan are intended to qualify as "incentive stock options" within the meaning of
Section 422 of the Internal Revenue Code of 1986, as amended (the "Code").
Nonstatutory stock options granted under the Option Plan are not intended to
qualify as incentive stock options under the Code. See "Federal Income Tax
Information" for a discussion of the tax treatment of options.

PURPOSE

The Board adopted the Option Plan to provide a means by which
employees, directors and consultants of the Company and its affiliates may be
given an opportunity to purchase stock in the Company, to assist in retaining
the services of such persons, to secure and retain the services of persons
capable of filling such positions and to provide incentives for such persons to
exert maximum efforts for the success of the Company and its affiliates. As of
December 31, 1998, approximately 171 of the approximately 171 employees,
directors and consultants of the Company and its affiliates are eligible to
participate in the Option Plan.

ADMINISTRATION

The Board administers the Option Plan. Subject to the provisions of the
Option Plan, the Board has the power to construe and interpret the Option Plan
and to determine the persons to whom and the dates on which options will be
granted, the number of shares of Common Stock to be subject to each option, the
time or times during the term of each option within which all or a portion of
such option may be exercised, the exercise price, the type of consideration and
other terms of the option.

The Board has the power to delegate administration of the Option Plan
to a committee composed of not fewer than two members of the Board. In the
discretion of the Board, a committee may consist solely of two or more outside
directors in accordance with Section 162(m) of the Code or solely of two or more
non-employee directors in accordance with Rule 16b-3 of the Securities Exchange
Act of 1934, as amended (the "Exchange Act"). The Board has not delegated
administration of the Option Plan to a committee of the Board. As used herein
with respect to the Option Plan, the "Board" refers to any committee the Board
may later appoint as well as to the Board itself.

The regulations under Section 162(m) of the Code require that the
directors who serve as members of the committee must be "outside directors." The
Option Plan provides that, in the Board's discretion, directors serving on the
committee may be "outside directors" within the meaning of Section 162(m). This
limitation would exclude from the committee directors who are (i) current
employees of the Company or an affiliate, (ii) former employees of the Company
or an affiliate receiving compensation for past services (other than benefits
under a tax-qualified pension plan), (iii) current and former officers of the
Company or an affiliate, (iv) directors currently receiving direct or indirect
remuneration from the Company or an affiliate in any capacity (other than as a
director), and (v) not otherwise considered an "outside director" for purposes
of Section 162(m). The definition of an "outside director" under Section 162(m)
is generally narrower than the definition of a "non-employee director" under
Rule 16b-3 of the Exchange Act.

ELIGIBILITY

Incentive stock options may be granted under the Option Plan only to
employees (including officers) of the Company and its affiliates. Employees
(including officers), directors, and consultants of both the Company and its
affiliates are eligible to receive nonstatutory stock options under the Option
Plan.

No option may be granted under the Option Plan to any person who, at
the time of the grant, owns (or is deemed to own) stock possessing more than 10%
of the total combined voting power of the Company or any affiliate of the
Company, unless the exercise price is at least 110% of the fair market value of
the stock subject to the option on the date of grant and the term of the option
does not exceed five years from the date of grant. In addition, the aggregate
fair market value, determined at the time of grant, of the shares of Common
Stock with respect to which incentive stock options are exercisable for the
first time by an optionee during any calendar year (under the Option Plan and
all other such plans of the Company and its affiliates) may not exceed $100,000.

No person may be granted options under the Option Plan for more than
500,000 shares of Common Stock during any calendar year ("Section 162(m)
Limitation").

STOCK SUBJECT TO THE OPTION PLAN

Following the approval of this Proposal by the stockholders, an
aggregate of 1,750,000 shares of Common Stock, plus up to 1,000,000 shares
issuable in connection with the Company's terminated 1988 Stock Option Plan (the
"1988 Plan"), is reserved for issuance under the Option Plan. If options granted
under the Option Plan or the 1988 Plan expire or otherwise terminate without
being exercised, the shares of Common Stock not acquired pursuant to such
options again

become available for issuance under the Option Plan. If the Company reacquires
stock issued under the Option Plan, the reacquired stock will again become
available for reissuance under the Option Plan.

TERMS OF OPTIONS

The following is a description of the permissible terms of options
under the Option Plan. Individual option grants may be more restrictive as to
any or all of the permissible terms described below.

Exercise Price; Payment. The exercise price of an incentive stock
option may not be less than 100% of the fair market value of the stock subject
to the option on the date of the grant and, in some cases (see "Eligibility"
above), may not be less than 110% of such fair market value. The exercise price
of a nonstatutory option may not be less than 85% of the fair market value of
the stock on the date of grant and, in some cases (see "Eligibility" above), may
not be less than 110% of such fair market value. If options were granted with
exercise prices below market value, deductions for compensation attributable to
the exercise of such options could be limited by Section 162(m) of the Code. See
"Federal Income Tax Information." As of March 26, 1999, the closing price of the
Company's Common Stock as reported on the Nasdaq National Market System was
$25.00 per share.

The exercise price of options granted under the Option Plan must be
paid either in cash at the time the option is exercised or at the discretion of
the Board, (i) by delivery of other Common Stock of the Company, (ii) pursuant
to a deferred payment arrangement or (iii) in any other form of legal
consideration acceptable to the Board.

Repricing. In the event of a decline in the value of the Company's
Common Stock, the Board has the authority to offer optionees the opportunity to
replace outstanding higher priced options with new lower priced options. To the
extent required by Section 162(m) of the Code, a repriced option is deemed to be
canceled and a new option granted. Both the option deemed to be canceled and the
new option deemed to be granted will be counted against the Section 162(m)
Limitation.

Option Exercise. Options granted under the Option Plan may become
exercisable in cumulative increments ("vest") as determined by the Board. The
Board has the power to accelerate the time during which an option may vest or be
exercised. In addition, options granted under the Option Plan may permit
exercise prior to vesting, but in such event the optionee may be required to
enter into an early exercise stock purchase agreement that allows the Company to
repurchase unvested shares, generally at their exercise price, should the
optionee's service terminate before vesting. To the extent provided by the terms
of an option, an optionee may satisfy any federal, state or local tax
withholding obligation relating to the exercise of such option by a cash payment
upon exercise, by authorizing the Company to withhold a portion of the stock
otherwise issuable to the optionee, by delivering already-owned Common Stock of
the Company or by a combination of these means.

Term. The maximum term of options under the Option Plan is 10 years,
except that in certain cases (see "Eligibility") the maximum term is five years.
Subject to the maximum term limitation noted above, options under the Option
Plan generally terminate three months after termination of the optionee's
service unless (i) such termination is due to the optionee's disability, in
which case the option may, but need not, provide that it may be exercised (to
the extent the option was exercisable at the time of the termination of service)
at any time within 12 months of such termination; (ii) the optionee dies before
the optionee's service has terminated, or within a period specified in the
option after termination of such service, in which case the option may, but need
not, provide that it may be exercised (to the extent the option was exercisable
at the time of the optionee's death) within 18 months of the optionee's death by
the person or persons to whom the rights to such option pass by will or by the
laws of descent and distribution; or (iii) the option by its terms specifically
provides otherwise. An optionee may designate a beneficiary who may exercise the
option following the optionee's death. Individual option grants by their terms
may provide for exercise within a longer period of time following termination of
service.

RESTRICTIONS ON TRANSFER

An optionee may not transfer an incentive stock option other than by
will or by the laws of descent and distribution. During the lifetime of the
optionee, only the optionee may exercise an incentive stock option. In addition
to transfers effective on death, an optionee may transfer a nonstatutory stock
option pursuant to certain domestic relations orders and the transferee may then
exercise such option according to its terms. Except as noted above, options
granted under the Option Plan are generally nontransferable. Shares subject to
repurchase by the Company under an early exercise stock purchase agreement may
be subject to restrictions on transfer that the Board deems appropriate.

ADJUSTMENT PROVISIONS

Transactions, such as a stock dividend, stock split, or certain types
of merger, consolidation, or reorganization, that do not involve the receipt of
consideration by the Company, may change the class and number of shares of
Common Stock subject to the Option Plan and outstanding options. In that event,
the Option Plan will be appropriately adjusted as to the class and the maximum
number of shares of Common Stock subject to the Option Plan and the Section
162(m) Limitation, and outstanding options will be adjusted as to the class,
number of shares and price per share of Common Stock subject to such options.

EFFECT OF CERTAIN CORPORATE EVENTS

The Option Plan provides that, in the event of a dissolution,
liquidation or sale of substantially all of the assets of the Company, specified
types of merger, or other corporate reorganization ("change in control"), to the
extent permitted by law, any surviving corporation will be required to either
assume options outstanding under the Option Plan or substitute similar options
for those outstanding under the Option Plan, or such outstanding options will
continue in full force and effect. If any surviving corporation declines to
assume options outstanding under the Option Plan, or to substitute similar
options, then, with respect to options held by optionees whose services have not
terminated, the vesting and the time during which such options may be exercised
may, at the discretion of the Board, be accelerated. An outstanding option will
terminate if the optionee does not exercise it before a change in control. The
acceleration of an option in the event of an acquisition or similar corporate
event may be viewed as an anti-takeover provision, which may have the effect of
discouraging a proposal to acquire or otherwise obtain control of the Company.

DURATION, AMENDMENT AND TERMINATION

The Board may suspend or terminate the Option Plan without stockholder
approval or ratification at any time or from time to time. Unless sooner
terminated, the Option Plan will terminate on October 29, 2005.

The Board may also amend the Option Plan at any time or from time to
time. However, no amendment will be effective unless approved by the
stockholders of the Company within 12 months before or after its adoption by the
Board if the amendment would (i) modify the requirements as to eligibility for
participation (to the extent such modification requires stockholder approval in
order for the Option Plan to satisfy Section 422 of the Code, if applicable, or
Rule 16b-3 of the Exchange Act); (ii) increase the number of shares reserved for
issuance upon exercise of options; or (iii) change any other provision of the
Option Plan in any other way if such modification requires stockholder approval
in order to comply with Rule 16b-3 of the Exchange Act or satisfy the
requirements of Section 422 of the Code or any Nasdaq or securities exchange
listing requirements. The Board may submit any other amendment to the Option
Plan for stockholder approval, including, but not limited to, amendments
intended to satisfy the requirements of Section 162(m) of the Code regarding the
exclusion of performance-based compensation from the limitation on the
deductibility of compensation paid to certain employees.

FEDERAL INCOME TAX INFORMATION

Long-term capital gains currently are generally subject to lower tax
rates than ordinary income or short-term capital gains. The maximum long-term
capital gains rate for federal income tax purposes is currently 20% while the
maximum ordinary income rate and short-term capital gains rate is effectively
39.6%. Slightly different rules may apply to optionees who acquire stock subject
to certain repurchase options or who are subject to Section 16(b) of the
Exchange Act.

Incentive Stock Options. Incentive stock options under the Option Plan
are intended to be eligible for the favorable federal income tax treatment
accorded "incentive stock options" under the Code.

There generally are no federal income tax consequences to the optionee
or the Company by reason of the grant or exercise of an incentive stock option.
However, the exercise of an incentive stock option may increase the optionee's
alternative minimum tax liability, if any.

If an optionee holds stock acquired through exercise of an incentive
stock option for at least two years from the date on which the option is granted
and at least one year from the date on which the shares are transferred to the
optionee upon exercise of the option, any gain or loss on a disposition of such
stock will be a long-term capital gain or loss if the optionee held the stock
for more than one year.

Generally, if the optionee disposes of the stock before the expiration
of either of these holding periods (a "disqualifying disposition"), then at the
time of disposition the optionee will realize taxable ordinary income equal to
the lesser of (i) the excess of the stock's fair market value on the date of
exercise over the exercise price, or (ii) the optionee's actual gain, if any, on
the purchase and sale. The optionee's additional gain or any loss upon the
disqualifying disposition will be a capital gain or loss, which will be
long-term or short-term depending on whether the stock was held for more than
one year.

To the extent the optionee recognizes ordinary income by reason of a
disqualifying disposition, the Company will generally be entitled (subject to
the requirement of reasonableness, the provisions of Section 162(m) of the Code
and the satisfaction of a tax reporting obligation) to a corresponding business
expense deduction in the tax year in which the disqualifying disposition occurs.

Nonstatutory Stock Options. Nonstatutory stock options granted under
the Option Plan generally have the following federal income tax consequences:

There are no tax consequences to the optionee or the Company by reason
of the grant of a nonstatutory stock option. Upon exercise of a nonstatutory
stock option, the optionee normally will recognize taxable ordinary income equal
to the excess, if any, of the stock's fair market value on the date of exercise
over the option exercise price. However, to the extent the stock is subject to
certain types of vesting restrictions, the taxable event will be delayed until
the vesting restrictions lapse unless the participant elects to be taxed on
receipt of the stock. With respect to employees, the Company is generally
required to withhold from regular wages or supplemental wage payments an amount
based on the ordinary income recognized. Subject to the requirement of
reasonableness, the provisions of Section 162(m) of the Code and the
satisfaction of a tax reporting obligation, the Company will generally be
entitled to a business expense deduction equal to the taxable ordinary income
realized by the optionee.

Upon disposition of the stock, the optionee will recognize a capital
gain or loss equal to the difference between the selling price and the sum of
the amount paid for such stock plus any amount recognized as ordinary income
upon exercise of the option (or vesting of the stock). Such gain or loss will be
long-term or short-term depending on whether the stock was held for more than
one year. Slightly different rules may apply to optionees who acquire stock
subject to certain repurchase options or who are subject to Section 16(b) of the
Exchange Act.

Potential Limitation on Company Deductions. Section 162(m) of the Code
denies a deduction to any publicly held corporation for compensation paid to
certain "covered employees" in a taxable year to the extent that compensation to
such covered employee exceeds $1 million. It is possible that compensation
attributable to stock options, when combined with all other types of
compensation received by a covered employee from the Company, may cause this
limitation to be exceeded in any particular year.

Certain kinds of compensation, including qualified "performance-based
compensation," are disregarded for purposes of the deduction limitation. In
accordance with Treasury regulations issued under Section 162(m), compensation
attributable to stock options will qualify as performance-based compensation if
the option is granted by a compensation committee comprised solely of "outside
directors" and either (i) the plan contains a per-employee limitation on the
number of shares for which options may be granted during a specified period, the
per-employee limitation is approved by the stockholders, and the exercise price
of the option is no less than the fair market value of the stock on the date of
grant, or (ii) the option is granted (or exercisable) only upon the achievement
(as certified in writing by the compensation committee) of an objective
performance goal established in writing by the compensation committee while the
outcome is substantially uncertain, and the option is approved by stockholders.

PROPOSAL 3

APPROVAL OF AMENDMENTS TO THE 1995 NON-EMPLOYEE DIRECTORS' STOCK OPTION PLAN

In September 1995, the Board adopted, and the stockholders subsequently
approved, the Company's 1995 Non-Employee Directors' Stock Option Plan (the
"Directors' Plan") covering 247,500 shares of the Company's Common Stock. As of
January 31, 1999, options (net of canceled or expired options) covering an
aggregate of 231,000 shares of the Company's Common Stock had been granted and
were outstanding under the Directors' Plan, and only 16,500 shares of Common
Stock (plus any shares that might in the future be returned to the Directors'
Plan as a result of cancellations or expiration of options or the reacquisition
by the Company of issued shares) remained available for future grant under the
Directors' Plan.

In January 1999, the Board amended the Directors' Plan, subject to
stockholder approval, to increase the number of shares of Common Stock
authorized for issuance under the Directors' Plan by 100,000 to a total of
347,500 shares. The Board adopted this amendment in order to ensure that the
Company can continue to grant stock options at levels determined appropriate by
the Board. In January 1999, the Board also amended the Directors' Plan, subject
to stockholder approval, (i) to decrease the amount of shares under
non-discretionary option grants from 16,500 to 10,000 shares for first-time
elected non-employee directors, (ii) to provide an annual option grant of 4,000
shares for each non-employee director immediately following each annual meeting
of stockholders, and (iii) increase the vesting period under the grants from
three years to four years. The Company's currently existing non-employee
directors will not receive any option grants under the Directors' Plan until
September 2001 when their current options under the Directors' Plan fully vest,
at which time they will be treated as first-time elected non-employee directors
and receive the 10,000 share initial grant at that time, and will receive the
4,000 share grants at the annual meetings of stockholders thereafter. In January
1999, the Board also amended the Directors' Plan, subject to stockholder
approval, to make certain technical amendments to the plan. The Board adopted
this amendment in order to conform the Directors' Plan to current provisions of
Rule 16b-3 under the Securities Exchange Act of 1934, and to revoke information
rights of the optionholders under such plan.

Stockholders are requested in this Proposal 3 to approve the amendments
to the Directors' Plan. The affirmative vote of the holders of a majority of the
shares present in person or represented by proxy and entitled to vote at the
meeting will be required to approve the amendments to the Directors' Plan.
Abstentions will be counted toward the tabulation of votes cast on proposals
presented to the stockholders and will have the same effect as negative votes.
Broker non-votes are counted towards a quorum, but are not counted for any
purpose in determining whether this matter has been approved.

THE BOARD OF DIRECTORS RECOMMENDS
A VOTE IN FAVOR OF PROPOSAL 3.

The essential features of the Directors' Plan are outlined below:

GENERAL

The Directors' Plan provides for the automatic grant of nonstatutory
stock options. Options granted under the Directors' Plan are not intended to
qualify as "incentive stock options" within the meaning of Section 422 of the
Code. See "Federal Income Tax Information" for a discussion of the tax treatment
of nonstatutory stock options.

PURPOSE

The Board adopted the Directors' Plan to provide a means by which
non-employees directors of the Company may be given an opportunity to purchase
stock in the Company, to assist in retaining the services of such persons, to
secure and retain the services of persons capable of filling such positions and
to provide incentives for such persons to exert maximum efforts for the success
of the Company. All of the current non-employee directors of the Company are
eligible to participate in the Directors' Plan.

ADMINISTRATION

The Board administers the Directors' Plan. The Board has the power to
construe and interpret the Directors' Plan but not to determine the persons to
whom or the dates on which options will be granted, the number of shares to be
subject to each option, the time or times during the term of each option within
which all or a portion of such option may be exercised, the exercise price, the
type of consideration or the other terms of the option.

The Board has the power to delegate administration of the Directors'
Plan to a committee composed of not fewer than two members of the Board. The
Board has not delegated administration of the Directors' Plan to a committee of
the Board. As used herein with respect to the Directors' Plan, the "Board"
refers to any committee the Board may later appoint as well as to the Board
itself.

ELIGIBILITY

The Directors' Plan provides that options may be granted only to
non-employee directors of the Company. A "non-employee director" is defined in
the Directors' Plan as a director of the Company who is not otherwise an
employee of the Company or any affiliate.

STOCK SUBJECT TO THE DIRECTORS' PLAN

Following the approval of this Proposal by the stockholders, an
aggregate of 347,500 shares of Common Stock is reserved for issuance under the
Directors' Plan. If options granted under the Directors' Plan expire or
otherwise terminate without being exercised, the shares of Common Stock not
acquired pursuant to such options again becomes available for issuance under the
Directors' Plan. If the Company reacquires unvested stock issued under the
Directors' Plan, the reacquired stock will again become available for reissuance
under the Directors' Plan.

TERMS OF OPTIONS

The following is a description of the terms of options under the
Directors' Plan. Individual option grants may not be more restrictive as to the
terms described below except as otherwise noted.

Non-Discretionary Grants. Following the approval of this Proposal by
the stockholders, each person who is elected for the first time to be a
non-employee director will be granted an option to purchase 10,000 (reduced from
16,500) shares of Common Stock, and each non-employee director will be granted
an additional option to purchase 4,000 shares of Common Stock immediately
following each annual meeting of stockholders. The Company's currently existing
non-employee directors will not receive any option grants under the Directors'
Plan until September 2001 when their current options under the Directors' Plan
fully vest, at which time they will be treated as first-time elected
non-employee directors and receive the 10,000 share initial grant at that time,
and will receive the 4,000 share grants at the annual meetings of stockholders
thereafter. If this Proposal is not approved, the number of shares subject to
options granted to non-employee directors under the Directors' Plan will
continue to be 16,500 shares every three years.

Exercise Price; Payment. The exercise price of options may not be less
than 100% of the fair market value of the stock subject to the option on the
date of the grant. At March 26, 1999, the closing price of the Company's Common
Stock as reported on the Nasdaq National Market System was $25.00 per share.

The exercise price of options granted under the Directors' Plan must be
paid (a) in cash at the time the option is exercised when the number of shares
being purchased is less than 1000 shares, or (b) when the number of shares being
purchased is at least 1000 shares (i) in cash at the time of exercise, (ii) by
delivery of shares of Common Stock of the Company if such Common Stock is
publicly traded or (iii) a combination of the methods specified in (i) and (ii).

Repricing. In the event of a decline in the value of the Company's
Common Stock, the Board has the authority to offer optionees the opportunity to
replace outstanding higher-priced options with new lower-priced options.

Option Exercise. Following the approval of this Proposal, options
granted under the Directors' Plan become cumulatively exercisable in equal
annual increments ("vest") over four (increased from three) years provided the
optionee's service as a director or employee of or consultant to the Company or
an affiliate has not earlier terminated. The Board does not have the power to
accelerate the time during which an option may vest or be exercised. Options
granted under the Directors' Plan do not permit exercise prior to vesting.

10.

Term. The term of options under the Directors' Plan is 10 years from
the date of grant. Options under the Directors' Plan terminate three months
after termination of the optionee's service unless the optionee dies before the
expiration of three months after termination of such service, in which case the
option may be exercised (to the extent the option was exercisable at the time of
the optionee's death) within 18 months of the optionee's death by the person or
persons to whom the rights to such option pass by will or by the laws of descent
and distribution. An optionee may designate a beneficiary who may exercise the
option following the optionee's death.

The option term is not extended in the event that exercise of the
option within these periods is prohibited.

Other Provisions. The option agreement may contain such other terms,
provisions and conditions not inconsistent with the Directors' Plan as
determined by the Board.

RESTRICTIONS ON TRANSFER

The optionee may not transfer an option otherwise than by will or the
laws of descent and distribution, or pursuant to a "domestic relations order"
within the meaning of Rule 16a-12 under the Securities Exchange Act of 1934.
During the lifetime of the optionee, an option may be exercised only by the
optionee (or by his guardian or legal representative or by a transferee pursuant
to a "domestic relations order").

ADJUSTMENT PROVISIONS

Transactions such as a merger, consolidation, reorganization, stock
dividend, or stock split, that do not involve the receipt of consideration by
the Company, may change the class and number of shares of Common Stock
authorized and/or outstanding. In that event, the Directors' Plan will be
appropriately adjusted as to the class and the maximum number of shares of
Common Stock subject to the Directors' Plan, and outstanding options will be
adjusted as to the class, number of shares and price per share of Common Stock
subject to such options.

EFFECT OF CERTAIN CORPORATE EVENTS

The Directors' Plan provides that, in the event of specified types of
merger, or other corporate reorganization ("change in control"), then the
vesting and the time during which such options may be exercised will be
accelerated. An outstanding option will terminate if the optionee does not
exercise it before a change in control. The acceleration of an option in the
event of an acquisition or similar corporate event may be viewed as an
anti-takeover provision, which may have the effect of discouraging a proposal to
acquire or otherwise obtain control of the Company.

DURATION, AMENDMENT AND TERMINATION

The Board may suspend or terminate the Directors' Plan without
stockholder approval or ratification at any time. Unless sooner terminated, the
Directors' Plan will terminate upon a change in control.

The Board may also amend the Directors' Plan at any time or from time
to time. However, no amendment will be effective unless approved by the
stockholders of the Company within 12 months before or after its adoption by the
Board if the amendment would (i) modify the requirements as to eligibility for
participation (to the extent such modification requires stockholder approval in
order for the Directors' Plan to satisfy Rule 16b-3 of the Exchange Act; (ii)
increase the number of shares reserved for issuance upon exercise of options; or
(iii) change any other provision of the Directors' Plan in any other way if such
modification requires stockholder approval in order to comply with Nasdaq or any
securities exchange listing requirements. However, subject to this Proposal, the
Board may not amend the Plan more than once every six months with respect to the
provisions of the Plan that relate to the amount, price and timing of grants,
other than to comport with changes in the Code, the Employee Retirement Income
Security Act of 1974, as amended ("ERISA"), or the rules thereunder. The Board
may, in its discretion, submit any other amendment to the Directors' Plan for
stockholder approval.

FEDERAL INCOME TAX INFORMATION

11.

to optionees who acquire stock subject to certain repurchase options or who are
subject to Section 16(b) of the Exchange Act.

Nonstatutory Stock Options. Nonstatutory stock options granted under
the Directors' Plan generally have the following federal income tax
consequences:

There are no tax consequences to the optionee or the Company by reason
of the grant of a nonstatutory stock option. Upon exercise of a nonstatutory
stock option, the optionee normally will recognize taxable ordinary income equal
to the excess of the stock's fair market value on the date of exercise over the
option exercise price. However, to the extent the stock is subject to certain
types of vesting restrictions, the taxable event will be delayed until the
vesting restrictions lapse unless the participant elects to be taxed on receipt
of the stock. If the optionee becomes an employee, the Company is required to
withhold from regular wages or supplemental wage payments an amount based on the
ordinary income recognized. Subject to the requirement of reasonableness and the
satisfaction of a tax reporting obligation, the Company will generally be
entitled to a business expense deduction equal to the taxable ordinary income
realized by the optionee.

PROPOSAL 4

RATIFICATION OF SELECTION OF INDEPENDENT AUDITORS

The Board of Directors has selected Ernst & Young, LLP ("Ernst &
Young") as the Company's
independent auditors for the fiscal year ending December 31, 19992000 and has
further directed that management submit the selection of independent auditorsErnst & Young, LLP for
ratification by the stockholders at the Annual Meeting. Ernst & Young, LLP has
audited the Company's financial statements since its inception in 1983.
Representatives of Ernst & Young, LLP are expected to be present at the Annual
Meeting, will have an opportunity to make a statement if they so desire and will
be available to respond to appropriate questions.

Stockholder ratification of the selection of Ernst & Young, LLP as the
Company's independent auditors is not required by the Company's By-laws or
otherwise. However, the Board is submitting the selection of Ernst & Young, LLP
to the stockholders for ratification as a matter of good corporate practice. If
the stockholders fail to ratify the selection, the Audit Committee and the Board
will reconsider whether or not to retain that firm. Even if the selection is
ratified, the Audit Committee and the Board in their discretion may direct the
appointment of different independent auditors at any time during the year if
they determine that such a change would be in the best interests of the Company
and its stockholders.

The affirmative vote of the holders of a majority of the shares present in
person or represented by proxy and entitled to vote at the Annual Meeting will
be required to ratify the selection of Ernst & Young.Young, LLP. Abstentions will be
counted toward the tabulation of votes cast on proposals presented to the
stockholders and will have the same effect as negative votes. Broker non-votes
are counted towards a quorum, but are not counted for any purpose in determining
whether this matter has been approved.

THE BOARD OF DIRECTORS RECOMMENDS A VOTE IN FAVOR OF PROPOSAL 4.

12.2.

4
7

SECURITY OWNERSHIP OF
CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

The following table sets forth certain information regarding the ownership
of the Company's Common Stock as of February 14, 199929, 2000 by: (i) each nominee for
director; (ii) each of the executive officers named in the Summary Compensation
Table; (iii) all executive officers and directors of the Company as a group; and
(iv) all those known by the Company to be beneficial owners of more than five
percent of its Common Stock.

Beneficial Ownership(1)
----------------------------
Number Percent
Name of Beneficial Owner of Shares of Class
BENEFICIAL OWNERSHIP(1)
-----------------------
NUMBER OF PERCENT OF
NAME OF BENEFICIAL OWNER SHARES CLASS
------------------------ --------- ----------

Kopp Investment Advisors, Inc.(2)........................... 1,878,405 19.3%
7701 France Ave. South, Ste. 500
Edina, Minnesota 55435
Chase Manhattan Corporation(2).............................. 985,075 10.1%
270 Park Avenue, 35th Floor
New York, New York 10017-2070
Putnam Investments(2)....................................... 648,000 6.7%
One Post Office Square
Boston, Massachusetts 02109
Pilgrim Baxter & Associates, Ltd.(2)........................ 590,900 6.1%
825 Duportail Road
Wayne, Pennsylvania 19087
Moshe H. Alafi(3)........................................... 424,840 4.4%
Harden M. McConnell, Ph.D.(4)............................... 356,600 3.7%
David L. Anderson(5)........................................ 188,907 1.9%
Joseph D. Keegan, Ph.D.(6).................................. 91,084 **
A. Blaine Bowman(7)......................................... 62,000 **
Robert J. Murray(8)......................................... 50,759 **
Gillian M.K. Humphries, Ph.D.(9)............................ 41,033 **
Paul Goddard, Ph.D.(10)..................................... 22,000 **
J. Allan Waitz, Ph.D.(11)................................... 22,000 **
Timothy A. Harkness(12)..................................... 19,478 **
Andre F. Marion(13)......................................... 16,500 **
Tony M. Lima(14)............................................ 10,969 **
John S. Senaldi(15)......................................... 8,517 **
All directors and executive officers as a group (13
persons)(16).............................................. 1,314,687 13.5%

- ----------------------------------------------- ------------- -------------
Kopp Investment Advisors, Inc. 2,112,425 22.2%
7701 France Ave. South, Ste. 500
Edina, MN 55435

Putnam Investments Inc. 639,800 6.7%
One P.O. Box Square
Boston, MA 02109

Munder Capital Management 555,825 5.8%
480 Pierce Street, Ste. 300
Birmingham, MI 48009

Franklin Resources Inc. 548,400 5.8%
777 Mariners Island Blvd., 6th Floor
San Mateo, CA 94404

Harden M. McConnell, Ph.D.(2) 453,400 4.8%

A. Blaine Bowman(3) 449,666 4.7%

Moshe H. Alafi(4) 419,340 4.4%

David L. Anderson(5) 187,380 2.0%

Joseph D. Keegan, Ph.D.(6) 50,526 *

Gillian M.K. Humphries, Ph.D.(7) 48,933 *

Robert J. Murray(8) 42,838 *

Paul Goddard, Ph.D.(9) 16,500 *

Andre F. Marion(10) 16,500 *

J. Allan Waitz, Ph.D(11) 16,500 *

Timothy A. Harkness(12) 3,750 *

Tony M. Lima -- --

All directors and executive officers as a 1,705,958 17.9%
group (12 persons) (13)

*---------------
** Less than one percent

(1) This tablePercentage of beneficial ownership is based uponon 9,709,971 shares of common
stock outstanding as of February 29, 2000, except as otherwise noted in the
footnotes. Beneficial ownership is determined in accordance with the rules
of the Securities and Exchange Commission and generally includes voting or
investment power with respect to securities. Shares of common stock subject
to options currently exercisable or exercisable within 60 days of February
29, 2000 are deemed outstanding for computing the percentage of the person
holding such options but are not deemed outstanding for computing the
percentage of any other person.

(2) Based on information supplied by officers, directors
and principal stockholders andas of December 31, 1999 reflected in Schedules 13D,
13F and 13G filed with the Securities and Exchange Commission (the "SEC"). Unless otherwise
indicated in the footnotes to this table and subject to community
property laws where applicable, the Company believes that each of the
stockholders named in this table has sole voting and investment power
with respect to the shares indicated as beneficially owned. Applicable
percentages are based on 9,507,226 shares outstanding on February 14,
1999, adjusted as required by rules promulgated by the SEC.

13.

(2) Consists of 453,400 shares held by the Harden M. McConnell and Sophia
G. McConnell Trust, of which Dr. McConnell is a co-trustee.Commission.

(3) Includes 382,166 shares beneficially owned by Dionex, of which Mr.
Bowman, a director of the Company, is President, Chief Executive
Officer and a director, and 16,500 shares that may be acquired within
60 days after February 14, 1999 pursuant to outstanding stock options.
Mr. Bowman disclaims beneficial ownership of the Dionex shares.

(4) Includes 402,840 shares beneficially owned by Alafi Capital Company, of
which Mr. Alafi, a director of the Company, is a general partner, and
16,50022,000 shares that may be acquired within 60 days after February 14,
199929, 2000
pursuant to outstanding stock options.

5
8

(4) Includes 351,100 shares held by the Harden M. McConnell and Sophia G.
McConnell Trust, of which Dr. McConnell is a co-trustee, and 5,500 shares
that may be acquired within 60 days after February 29, 2000 pursuant to
outstanding stock options.

(5) Includes: (i) 28,086 shares beneficially owned by Sutter Hill Ventures,
a California limited partnership ("Sutter Hill Ventures"), of which Mr.
Anderson, a director of the Company, is a general partner, (ii) 14,661Includes 14,710 shares beneficially owned by Anvest, L.P., of which Mr.
Anderson is a general partner, and (iii) 16,50022,000 shares that may be acquired
within 60 days after February 14, 199929, 2000 pursuant to outstanding stock
options.

Mr.
Anderson disclaims beneficial ownership of shares held by Sutter Hill
Ventures and Anvest, L.P., and individuals and entities associated with
Sutter Hill Ventures and Anvest, L.P., except as to the shares held of
record in his name and his proportionate partnership interest in the
shares held of record by Sutter Hill Ventures and Anvest, L.P.

(6) Includes 37,75071,750 shares that may be acquired within 60 days after February
14, 199929, 2000 pursuant to outstanding stock options and periodic stock grants.

(7) Includes 13,000 shares beneficially owned by the Gillian Mavis
Humphries and Simon Anthony Humphries, trustees of the Marital Trust of
the Humphries 1991 Living Trust, of which Dr. Humphries is a
co-trustee, and 35,53322,000 shares that may be acquired within 60 days after February
14, 199929, 2000 pursuant to outstanding stock options.

(8) Includes 40,83250,165 shares that may be acquired within 60 days after February
14, 199929, 2000 pursuant to outstanding stock options.

(9) Includes 41,033 shares that may be acquired within 60 days after February
29, 2000 pursuant to outstanding stock options.

(10) Includes 22,000 shares that may be acquired within 60 days after February
29, 2000 pursuant to outstanding stock options.

(11) Includes 22,000 shares that may be acquired within 60 days after February
29, 2000 pursuant to outstanding stock options.

(12) Includes 11,500 shares that may be acquired within 60 days after February
29, 2000 pursuant to outstanding stock options and periodic stock grants.

(13) Includes 16,500 shares that may be acquired within 60 days after February
14, 199929, 2000 pursuant to outstanding stock options.

(10)(14) Includes 16,50010,000 shares that may be acquired within 60 days after February
14, 199929, 2000 pursuant to outstanding stock options.

(11)(15) Includes 16,5006,200 shares that may be acquired within 60 days after February
14, 199929, 2000 pursuant to outstanding stock options.

(12)options, all of which will vest upon
a change of control of the Company.

(16) Includes 1,250 shares that may be acquired within 60 days after
February 14, 1999 pursuant to periodic stock grants.

(13) Includes 827,753768,650 shares held by entities affiliated with certain directors
and 214,990322,648 shares that certain directors and officers have the right to
acquire within 60 days after February 14, 199929, 2000 pursuant to the exercise of
outstanding stock options and/or periodic stock grant rights. See Footnotes
(2) through (12)(15).

SECTION 16(A) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE

Section 16(a) of the Securities Exchange Act of 1934 (the "1934 Act")
requires the Company's directors and executive officers, and persons who own
more than ten percent of a registered class of the Company's equity securities,
to file with the SEC initial reports of ownership and reports of changes in
ownership of Common Stock and other equity securities of the Company. Officers,
directors and greater than ten percent stockholders are required by SEC
regulation to furnish the Company with copies of all Section 16(a) forms they
file.

To the Company's knowledge, based solely on a review of the copies of such
reports furnished to the Company and written representations that no other
reports were required, during the fiscal year ended December 31, 1998,1999, all
Section 16(a) filing requirements applicable to its officers, directors and
greater than ten percent beneficial owners were 14.
complied with, except that a
statement of change in beneficial ownership report was filed late by Mr. Harkness, Mr. Senaldi, and Dr. Keegan.
The failure to timely file such reportsreport of ownership was due to administrative
error.error and was corrected by the filing of a year-end Form 5.

6
9

EXECUTIVE OFFICERS OF THE COMPANY

The executive officers and certain key employees of the Company and
their ages and positions as of March 31, 1999The executive officers and certain key employees of the Company and their
ages and positions as of February 29, 2000 are as follows:

Name Age Position
- ----------------------------------------------NAME AGE POSITION
---- --- -------- -----------------------------------------

Joseph D. Keegan, Ph.D. 45...................... 46 President, Chief Executive Officer
Timothy A. Harkness 32Harkness........................... 33 Vice President, Chief Financial Officer
Tony M. Lima.................................. 41 Vice President, Sales and Service
John S. Senaldi............................... 35 Vice President, Marketing
Robert J. Murray.............................. 52 Vice President, Operations
Gillian M.K. Humphries, Ph.D. 60................ 61 Vice President, Tony M. Lima 40 Vice President

Robert J. Murray 51 Vice President

John S. Senaldi 34 Vice PresidentResearch and Development

Joseph D. Keegan, Ph.D., was appointedhas served as our President and Chief Executive
Officer of the Company effectivesince March 30, 1998. From 1992 to 1998, Dr. Keegan served in various
positions at Becton Dickinson and Company, a research and diagnostic company,
including the positions of Vice President, Sales and Service, Vice President,
General Manager of the Immunocytometry Systems Division and, most recently,
President of the Worldwide Tissue Culture Business. From 1987 to 1992, he was
employed by LEICA, Inc., a microscope manufacturer, where he held various senior
management positions. Dr. Keegan holds a Ph.D. in Chemistry from Stanford
University.

Timothy A. Harkness was appointedhas served as our Vice President, Finance and Chief
Financial Officer of the Company effectivesince July 9, 1998. From 1997 to 1998, Mr. Harkness was Vice
President of Business Development at Vivra Specialty Partners, a physician
practice management company. Previously, Mr. Harkness was with Montgomery
Securities in the Health Care Investment Banking Group from 1994 to 1997 and
with Arthur Andersen & Co. from 1989 to 1992. Mr. Harkness holds an MBA from
Stanford University Graduate School of Business and is a CPA.

Gillian M.K. Humphries, Ph.D., has served as a Vice President of the
Company since March 1990. Dr. Humphries served as a consultant to the Company
since its inception in 1983. In 1984, Dr. Humphries joined the Company on a full
time basis as a research scientist and, from 1985 to 1990, she served as
Director of MAXline and Cytosensor Development. Dr. Humphries holds a Ph.D. in
Biochemistry from Stanford University and an MS in Biochemistry from San Jose
State University.

Tony M. Lima was appointedhas served as Vice President, in charge of Worldwide Sales and
Service, of the Company effectivesince July 28, 1998. Previously, Mr. Lima was Manager, Sales
and Marketing at Cavro Scientific Instruments during a portion of 1998,
President/CEO of Aydius, Inc. from 1996 to 1997, and Vice President, Customer
Services of Behring Diagnostics (formerly Syva Company) from May 1995 to March
1996. From 1981 to May 1995 he was employed by Syva Co., a global clinical
diagnostics company, where he held various senior management positions in
England, Belgium and the United States. Mr. Lima holds a higher TEC Degree in
Electronics from Kingston College London, England.

Robert J. Murray has served as a Vice President of the Company since
July 1995. Mr. Murray served as the Company's Director of Operations from 1993
to 1995. During 1993, Mr. Murray was a consultant to Tandem Computers,
Incorporated, a computer manufacturer. From 1991 to 1993, Mr. Murray was Vice
President of Manufacturing at Electromer Corporation, an electronic component
company, and from 1989 to 1991, a Vice President of Comptronix Corp., a contract
manufacturing company. Mr. Murray holds an MS in Electrical Engineering from San
Jose State University.

John S. Senaldi was appointedhas served as Vice President, in charge of Worldwide
Marketing of the Company effectivesince August 6, 1998. From 1993 to 1998, Mr. Senaldi
served in various management positions at Becton Dickinson and Company, a
research and diagnostic company, including the positions of Director of Business
Development and Senior Product Manager in both Europe and North America for
Becton's Diabetes Healthcare business. Most recently, he was in a Program
Management role for Becton's Immunocytometry Systems Division. Prior to joining
Becton Dickinson, 15.
Mr. Senaldi held various management positions in manufacturing
and marketing with General Electric Company's Medical Systems Business Group and
in engineering functions with several start-up medical diagnostic companies. Mr.
Senaldi holds an MBA from Harvard Business School, an MSEE from Rensselaer
Polytechnic Institute and a BS in Engineering from Trinity College.

Robert J. Murray has served as a Vice President, in charge of Worldwide
Operations, since July 1995. Mr. Murray served as the Company's Director of
Operations from 1993 to 1995. During 1993, Mr. Murray was a consultant to Tandem
Computers, Incorporated, a computer manufacturer. From 1991 to 1993, Mr. Murray
was Vice President of Marketing and Manufacturing at Electromer Corporation, an
electronic component company, and from 1989 to 1991, was Vice President and
General Manager of Comptronix Corp., a contract manufacturing company. Prior to
joining Comptronix Corp., Mr. Murray was Vice President of Operations of Gould,
Inc., a diversified conglomerate. Mr. Murray holds an MS in Electrical
Engineering from San Jose State University and a BS from UC Davis.

7
10

EXECUTIVE COMPENSATION

COMPENSATION OF DIRECTORS

Beginning in January 1999,For the year 2000, each member of the Company's Board of Directors will
receive $1,000 for each Board meeting attended by such director and $500 for
each Board committee meeting attended. In addition, the members of the Board may
be reimbursed for out-of-pocket and travel expenses incurred in connection with
attendance at Board and committee meetings.

Since the Company was founded in 1983, Dr. McConnell has provided
consulting services to the Company regarding, among other matters, the Company's
research and development activities and business strategy. Dr. McConnell is
currently paid $5,000 per month for such services.

During 1995, the Board adopted the 1995 Non-Employee Directors' Stock
Option Plan (the "Directors' Plan") to provide for the automatic grant of
options to purchase shares of Common Stock to non-employee directors of the
Company ("Non-Employee Directors"). Prior to the approval of Proposal 3 by the
stockholders, theThe maximum number of shares of Common Stock
that may be issued pursuant to options granted under the Directors' Plan is
247,500. After the
approval of Proposal 3 by the stockholders, the maximum number of shares of
Common Stock that may be issued pursuant to options granted under the Directors'
Plan will be 347,500.

Prior to the approval of Proposal 3 by the stockholders, pursuantPursuant to the terms of the Directors' Plan, each Non-Employee Director is
automatically granted an option to purchase 16,500 shares of Common Stock on the
date of his or her election to the Board. On the date of adoption of the
Directors' Plan, each person who was then a Non-Employee Director of the Company
was granted an option to purchase 16,500 shares of Common Stock of the Company
under the Directors' Plan, at an exercise price of $5.25 per share. Thereafter
each Non-Employee Director willis automatically be granted an option to purchase an
additional 16,500 shares of Common Stock under the Directors' Plan upon full
vesting of any stock option previously granted to such person under the
Directors' Plan. After the approval of Proposal 3 by the stockholders, eachEach newly elected Non-Employee Director will beis automatically
granted an option to purchase 10,000 shares of Common Stock on the date of his
or her initial election to the Board and each Non-Employee Director will be
granted an option to purchase an additional 4,000 shares of Common Stock
immediately following each annual meeting of stockholders. The Company's
currently existing non-employee directors will not receive any option grants
under the Directors' Plan until September 2001 when their current options under
the Directors' Plan fully vest, at which time they will be treated as first-time
elected non-employee directors and receive the 10,000 share initial grant at
that time, and will receive the 4,000 share grants at the annual meetings of
stockholders thereafter.

Outstanding options under the Directors' Plan will vest over a period of
three years from the date of grant in equal annual installments. The exercise
price of options granted under the Directors' Plan must equal or exceed the fair
market value of the Common Stock on the date of grant. No option granted under
the Directors' Plan may be exercised after the expiration of ten years from the
date it was granted. Options granted under the Directors' Plan are generally
non-transferable. The Board may suspend or terminate the Directors' Plan at any
time. In the event of a merger or consolidation, or a reverse merger or
reorganization in which the Company is not the surviving corporation, options
outstanding under the Directors' Plan will automatically become fully vested and
will terminate if not exercised prior to such event. After the approval of
Proposal 3, futureFuture option grants under
the Directors' Plan will vest over a period of four years from the date of
grant.

During the last fiscal year, in accordance with the terms of the
Directors' Plan prior to the amendment for which stockholder approval is being
solicited as set forth in Proposal 3, the Company granted options covering
16,500 shares to each Non-Employee Director, at an exercise price per share of
$14.50. The fair market value of such Common Stock on the date of grant was
$14.50 per share (based on the closing sales price reported in the Nasdaq
National Market System for the date of grant). As of March 15, 1999, 16,500
options had been exercised under the Directors' Plan.

16.8
11

COMPENSATION OF EXECUTIVE OFFICERS

SUMMARY OF COMPENSATION

The following table shows for the fiscal years ended December 31, 1996,
1997 and 1998, compensation awarded or paid to, or earned by, the Company's
Chief Executive Officer, its other four most highly compensated executive
officers at December 31, 1998 and a former executive officer who ceased serving
as an executive officer during fiscal year 1998Summary of Compensation

The following table shows for the fiscal years ended December 31, 1997,1998
and 1999, compensation awarded or paid to, or earned by, the Company's Chief
Executive Officer and its other five most highly compensated executive officers
at December 31, 1999 (the "Named Executive Officers"):

SUMMARY COMPENSATION TABLE

Annual Compensation Long-Term
LONG-TERM
COMPENSATION
ANNUAL COMPENSATION AWARDS
------------------- Compensation
Awards
---------------------------
Restricted
Stock Securities All Other
Salary Bonus Award(s) Underlying Compensation
Name and Principal Position Year-------------------------
RESTRICTED SECURITIES ALL OTHER
SALARY BONUS STOCK UNDERLYING COMPENSATION
NAME AND PRINCIPAL POSITION YEAR ($) ($)(1) AWARD(S)($) Options (#)OPTIONS(#) ($)
-
--------------------------- ---- -------- -------- ----------- --------------------- ------------

Joseph D. Keegan, Ph.D.(2)............. 1999 $296,670 $165,000 -- 50,000 $ 14,540(4)
President, Chief 1998 $210,015 $105,000210,015 105,000 $577,500(3) 170,000 $163,962(4)
President, Chief
Executive Officer(2)

Andre F. Marion(5) 1998 86,376 - - 16,500 -
Interim President, Chief 1997 72,916 - - - -163,962(5)
Executive Officer
Timothy A.Tim Harkness(6) 1998 74,479 35,750 $167,500(7) 75,000 89,124(8)........................ 1999 177,083 79,688 -- 30,000 1,859(7)
Vice President, Chief Financial 1998 74,479 35,750 $167,500(8) 75,000 89,124(9)
Officer
Tony Lima(10).......................... 1999 179,170 71,668 -- 30,000 2,100(7)
Vice President, Sales and Service 1998 76,291 36,619 -- 50,000 1,755(7)

John Senaldi(11)....................... 1999 164,170 65,668 -- 30,000 1,792(7)
Vice President, Marketing 1998 64,707 31,000 $ 36,875(12) 46,000 31,622(13)

Robert J .Murray....................... 1999 160,683 64,273 -- 20,000 2,231(7)
Vice President, Operations 1998 124,600 50,000 -- -- 2,161(7)
1997 118,920 38,649 -- 10,000 2,146(7)

Gillian M.K. Humphries, Ph.D. ......... 1999 159,591 63,836 -- 25,000 3,499(7)
Vice President, Research and 1998 131,450 63,120 - - 3,319(9)
Vice President-- -- 3,319(7)
Development 1997 118,013 38,354 --- 16,000 3,210(9)
1996 119,166 40,000 - - 1,620(9)

Tony M. Lima(10) 1998 76,291 36,619 - 50,000 1,755(9)
Vice President

Robert J. Murray 1998 124,600 50,000 - - 2,161(9)
Vice President 1997 118,920 38,649 - 10,000 2,146(9)
1996 112,440 32,500 - - 571(9)

3,210(7)

- ---------------
(1) Represents amounts accrued by the Company in 1996, 1997 and 1998, but
paid in 1997, 1998 and 1999, but paid
in 1998, 1999 and 2000 at the election of the Company.

(2) Dr. Keegan has served as President and Chief Executive Officer of the
Company since March 1998.

(3) Consists of an award of 30,000 shares of restricted stock valued at
$577,500 on the date of grant.

(4) Consists of the following payments made by the Company: (i) $150,000
signing bonus upon employment with the Company on March 30, 1998, (ii)
$2,280 for the taxable portion of group life insurance and the
Company's discretionary contribution to employee's 401(k) accounts,
(iii) $2,682 for relocation costs reimbursed to the employee, and (iv)
$9,000 for auto costs reimbursed to the employee.

(5) Mr. Marion served as Interim President and Chief Executive Officer of
the Company between October 1997 and March 1998.

17.

(6) Mr. Harkness has served as Vice President Finance and Chief Financial
Officer of the Company since July 1998.

(7) Consists of an award of 10,000 shares of restricted stock valued at
$167,500 on the date of grant.

(8) Consists of the following payments made by the Company: (i) $87,500
signing bonus upon accepting a new position with the Company on July 9,
1998, and (ii) $1,624 for the taxable portion of group life insurance
and the Company's discretionary contribution to employee's 401(k)
accounts.

(9) Represents the taxable portion of group life insurance paid by the
Company and the Company's discretionary contribution to employee's
401(k) accounts.

(10) Mr. Lima has served as Vice President Worldwide Sales and Service of
the Company since July 1998.

18.

EMPLOYMENT AGREEMENTS Chief Executive Officer Key Employee Agreementof the
Company since March 1998.

(3) Consists of an award of 30,000 shares of restricted stock valued at
$577,500 on the date of grant.

(4) Consists of the following payments made by the Company: (i) $1,040 for the
taxable portion of group life insurance, (ii) $1,500 for the Company's
discretionary contribution to employee's 401(k) account, and (iii) $12,000
for use of automobile by employee.

(5) Consists of the following payments made by the Company: (i) $150,000
signing bonus upon employment with the Company on March 30, 1998, (ii)
$2,280 for the taxable portion of group life insurance and the Company's
discretionary contribution to employee's 401(k) accounts, (iii) $2,682 for
relocation costs reimbursed to the employee, and (iv) $9,000 for automobile
costs reimbursed to the employee.

(6) Mr. Harkness has served as Vice President of Finance and Chief Financial
Officer of the Company since July 1998.

(7) Represents the taxable portion of group life insurance paid by the Company
and the Company's discretionary contribution to employee's 401(k) account.

(8) Consists of an award of 10,000 shares of restricted stock valued at 167,500
on the date of grant.

(9) Consists of the following payments made by the Company: (i) $87,500 signing
bonus upon accepting a new position with the Company on July 9, 1998, and
(ii) $1,624 for the taxable portion of group life insurance and the
Company's discretionary contribution to employee's 401(k) account.

(10) Mr. Lima has served as Vice President of Worldwide Sales and Service of the
Company since July 1998.

(11) Mr. Senaldi has served as Vice President of Marketing since August 1998.

(12) Consists of an award of 2,500 shares of restricted stock valued at $36,875
on the date of grant.

9
12

(13) Consists of the following payments made by the Company: (i) $30,000 signing
bonus upon accepting a position with the Company on August 6, 1998, (ii)
$1,622 for the taxable portion of group life insurance and the Company's
discretionary contribution to employee's 401(k) accounts.

EMPLOYMENT AGREEMENTS

CHIEF EXECUTIVE OFFICER KEY EMPLOYEE AGREEMENT

On March 11, 1998, Joseph D. Keegan, Ph.D., entered into a Key Employee
Agreement with the Company that provided for the following:

o- Dr. Keegan was appointed as President and Chief Executive Officer,
effective March 30, 1998 (the "Employment Date").

o- Dr. Keegan will be paid an annual base salary of $280,000.

o- Dr. Keegan will receive a one time "signing bonus" of $150,000. Such
bonus is subject to repayment if Dr. Keegan terminates his employment
with the Company within the first year of his employment.

o- Dr. Keegan is eligible to receive an annual performance bonus up to 50%
of his base salary based on achievement of certain goals specified by the
Board.

o- The Board will grant Dr. Keegan options to purchase 170,000 shares of the
Company's Common Stock with an exercise price equal to the fair market
value of the Common Stock on the Employment Date. The Options will vest
over five years with 34,000 shares vesting on the first anniversary of
the Employment Date and 8,500 shares vesting every June 30, September 30,
December 30, and March 30 thereafter. Vesting ceases if Dr. Keegan's
employment terminates at any time for any reason with the following
exceptions: (a) Dr. Keegan is retained by the Company in a
post-employment consulting position, as specified, thus providing for an
additional year of vesting, or (b) if Dr. Keegan is demoted without
cause, as defined in the agreement, within two years following certain
defined transactions, then vesting of the remaining unvested options will
accelerate such that Dr. Keegan will be fully vested with respect to the
options to purchase 170,000 shares of the Company's Common Stock.

o- The Board will grant Dr. Keegan an aggregate of 30,000 shares of the
Company's Common Stock subject to applicable securities laws
restrictions, over two years. A total of 3,750 shares will be granted
following the completion of each quarter of service with the Company as
President and Chief Executive Officer on June 30, 1998 and 1999,
September 30, 1998 and 1999, December 30, 1998 and 1999, and March 30,
1999 and 2000. Upon granting, each individual grant will be fully earned
and vested. Granting of stock ceases if Dr. Keegan's employment
terminates at any time for any reason with the following exception: if
Dr. Keegan is demoted without cause, as defined in the agreement, within
two years following certain defined transactions, then granting of the
remaining ungranted shares will accelerate such that Dr. Keegan will be
granted a total of 30,000 shares of the Company's Common Stock. The
Company agrees to loan Dr. Keegan amounts required for the payment of tax
obligations related to these share grants. oAs of December 31, 1994
$235,181 was outstanding under these loans.

- In the event Dr. Keegan's employment is terminated by the Company without
cause, as defined in the agreement, the Company shall provide Dr. Keegan
with a one-year consulting agreement, as defined, and outplacement
services.

Chief Financial Officer Employee AgreementCHIEF FINANCIAL OFFICER EMPLOYEE AGREEMENT

On July 8, 1998, Timothy A. Harkness, entered into an Employee Agreement
with the Company that provided for the following:

o- Mr. Harkness was appointed as Vice President of Finance and Chief
Financial Officer, effective July 9, 1998 (the "Employment Date").

o10
13

- Mr. Harkness will be paid an annual base salary of $150,000. His salary
will increase to $162,000 per year in 3 months and $175,000 per year in 6
months upon certain milestone achievements.

o- Mr. Harkness will receive a one time hiring bonus of $87,500.

o- Mr. Harkness is eligible to participate in the Company's bonus plan at
40% of his base salary prorated for employment tenure.

19.

o- Mr. Harkness is eligible to receive options to purchase 75,000 shares of
the Company's Common Stock. The options will vest over five years with
15,000 shares vesting on the first anniversary of the Employment Date and
3,750 shares vesting every quarter thereafter.

o- Mr. Harkness is eligible to receive an aggregate of 10,000 shares of the
Company's Common Stock. A total of 1,250 shares will be granted following
each quarter of service with the Company. Upon granting, each share will
be fully earned and vested. If Mr. Harkness is terminated without cause
within the first two years, then (i) the granting of shares will
accelerate such that Mr. Harkness will receive 10,000 shares of the
Company's Common Stock and (ii) Mr. Harkness will receive a one-time
severance payment equal to the prior 6 months compensation. The Company
agrees to loan Mr. Harkness amounts required for the payment of tax
obligations related to these share grants. oAs of December 31, 1999
$61,806 was outstanding under these loans.

- In the event of a change of control resulting in either termination or
demotion, all of Mr. Harkness' stock options and shares will become fully
vested on such date. In addition, Mr. Harkness would be granted a
one-time severance payment equal to the last 12 months compensation.

Vice President Employment AgreementVICE PRESIDENT EMPLOYMENT AGREEMENT

On July 9, 1998, Tony M. Lima, Vice President of Worldwide Sales and
Service, entered into an employment agreement with the Company that provided for
the following:

o- Mr. Lima'sLima will be paid an annual base salary of $175,000.

o- Mr. Lima is eligible to participate in the Company's bonus plan at 40% of
his base salary prorated from the time he has been employed, with a
guaranteed minimum bonus of $30,000 under the plan for the 1998 plan
year.

o- Mr. Lima is eligible to receive options to purchase 50,000 shares of the
Company's Common Stock. The options will vest over five years with 10,000
shares vesting on each of the first and second anniversary of the
employment date and 2,500 shares vesting quarterly following the second
anniversary of the employment date.

Vice President Employment AgreementVICE PRESIDENT EMPLOYMENT AGREEMENT

On July 13, 1998, John S. Senaldi, Vice President of Worldwide Marketing,
entered into an employment agreement with the Company that provided for the
following:

o- Mr. Senaldi'sSenaldi will be paid an annual base salary of $160,020. Mr. Senaldi
will receive a one time signing bonus of $30,000.

o- Mr. Senaldi is eligible to participate in the Company's bonus plan at 40%
of his base salary prorated from the time he has been employed, with a
guaranteed minimum bonus of $30,000 under the plan for the 1998 plan
year.

o- Mr. Senaldi will be eligible to receive options to purchase 46,000 shares
of the Company's Common Stock. The options will vest over five years with
10,000 shares vesting on each of the first and second anniversary of the
employment date and 2,500 shares vesting quarterly following the second
anniversary of the employment date.

o- Mr. Senaldi will be eligible to receive an aggregate of 2,500 shares of
the Company's Common Stock. The shares will be granted ratably and
quarterly over a period of two years.
o11
14

- In the event of a Change of Control, all of Mr. Senaldi's stock options
and shares will become fully vested at such date.

20.

STOCK OPTION GRANTS AND EXERCISES

The Company grants options to its executive officers under its 1988 Stock
Option Plan (the "1988 Plan") and 1995 Stock Option Plan (the "1995 Plan" and
collectively with the 1988 Plan, the "Option Plans"). The 1988 Plan was
terminated upon establishment of the 1995 Plan. As of January 31, 1999,February 29, 2000, options
to purchase a total of 885,4831,777,152 shares were outstanding under the Option Plans
and options to purchase 212,935513,715 shares remained available for grant under the
1995 Plan.

The following tables show for the fiscal year ended December 31, 1998,The following tables show for the fiscal year ended December 31, 1999,
certain information regarding options granted to, exercised by, and held at year
end by, the Named Executive Officers:

OPTION GRANTS IN LAST FISCAL YEAR

OPTION GRANTS IN LAST FISCAL YEAR
Option Grants in Last Fiscal Year
---------------------------------
Percentage
Of Total
Options Potential Realizable
Number of Granted to Value at Assumed
Securities Employees Exercise Annual Rates of Stock
Underlying in Fiscal Price Expiration Price Appreciation for
Name Options Granted Year(1)--------------------------------------------------- POTENTIAL REALIZABLE VALUE
PERCENTAGE OF AT ASSUMED ANNUAL
NUMBER OF TOTAL OPTIONS RATES OF STOCK PRICE
SECURITIES GRANTED TO APPRECIATION FOR
UNDERLYING EMPLOYEES IN EXERCISE OPTION TERM(3)
OPTIONS FISCAL PRICE EXPIRATION ---------------------------
NAME GRANTED YEAR(1) ($/Sh)SH)(2) Date Option Term(3)DATE 5% 10%
- ------------------------------- ------------------- ---------- ------------- --------- ---------- ----------- --------- ----------- ------------------------------------

Joseph D. Keegan(4) 170,000 38 19.125 03/29/08 $2,044,694 $5,181,655
Andre F. Marion(5) 16,500 14(6) 14.50 09/12/08 150,463 381,303.......... 50,000 9.13% $26.625 05/19/2009 $867,757 $2,170,303
Timothy A. Harkness(4) 75,000 17 16.75 07/09/08 790,048 2,002,139....... 30,000 5.48% 26.625 05/19/2009 520,655 1,302,181
Tony M. Lima(4).............. 30,000 5.48% 26.625 05/19/2009 520,655 1,302,181
John S. Senaldi(4)........... 30,000 5.48% 26.625 05/19/2009 520,655 1,302,181
Robert J. Murray(4).......... 20,000 3.65% 26.625 05/19/2009 347,103 868,121
Gillian M.K. Humphries -- -- -- -- -- --
Tony M. Lima(7) 50,000 11 17.625 07/27/08 554,213 1,404,486
Robert J. Murray -- -- -- -- -- --

(1) Based on 447,700 shares subject to options granted in 1998.

(2) The exercise price is equal to 100% of the fair market value of the
Common Stock on the date of the Grant.

(3) The potential realizable value is calculated based on the term of the
option at its time of grant (10 years) and is calculated by assuming
that the stock price on the date of grant as determined by the Board of
Directors appreciates at the indicated annual rate compounded annually
for the entire term of the option and that the option is exercised and
sold on the last day of its term for the appreciated price. The 5% and
10% assumed rates of appreciation are derived from the rules of the
Securities and Exchange Commission and do not represent the Company's
estimate or projection of the future Common Stock price.

(4) The options have a ten-year term, subject to earlier termination upon
death, disability or termination of employment. Options vest at the
rate of 20% on the first anniversary of the date of grant and 5% each
quarter thereafter for 4 years. Messrs. Keegan and Harkness also
received restricted stock grants during 1998. See "Employment
Agreements."

(5) The options have a ten-year term, subject to the earlier termination
upon death, disability or termination of employment. Options vest
annually over a period of three years.

(6) Based on 115,500 shares subject to options granted under the 1995
Directors' Plan.

(7) The options have a ten-year term, subject to the earlier termination
upon death, disability or termination of employment. Options vest at
the rate of 20% on the first and second anniversary of the date of
grant and 5% each quarter thereafter for 4 years.
Humphries(4).... 25,000 4.57% 26.250 05/19/2009 433,879 1,085,151

21.- ---------------
(1) Based on 547,500 shares subject to options granted in 1999.

(2) The exercise price is equal to 100% of the fair market value of the Common
Stock on the date of the Grant.

(3) The potential realizable value is calculated based on the term of the option
at its time of grant (10 years) and is calculated by assuming that the stock
price on the date of grant as determined by the Board of Directors
appreciates at the indicated annual rate compounded annually for the entire
term of the option and that the option is exercised and sold on the last day
of its term for the appreciated price. The 5% and 10% assumed rates of
appreciation are derived from the rules of the Securities and Exchange
Commission and do not represent the Company's estimate or projection of the
future Common Stock price.

(4) The options have a ten-year term, subject to earlier termination upon death,
disability or termination of employment. Options vest at the rate of 25% per
year.

12
15

AGGREGATED OPTION EXERCISES IN LAST FISCAL YEAR AND FISCAL YEAR-END OPTION
VALUES

Number of
Securities Value of
Underlying Unexercised
Unexercised In-the-Money
Options at FY-End Options at FY-End
Shares Acquired on Value Realized (#) Exercisable/ ($NUMBER OF
SECURITIES
UNDERLYING VALUE OF UNEXERCISED
UNEXERCISED OPTIONS IN-THE-MONEY OPTIONS
AT FY-END(#) AT FY-END($)
Exercisable/
Name Exercise (#) ($SHARES ACQUIRED EXERCISABLE/ EXERCISABLE/
NAME ON EXERCISE(#) VALUE REALIZED($) Unexercisable Unexercisable(1)
- ----------------------------- ------------------UNEXERCISABLE UNEXERCISABLE(1)
---- --------------- -------------------------------------- ------------------- --------------------

Joseph D. KeeganKeegan............. -- -- 0/170,000 0/446,250
Andre F. Marion59,500/160,500 1,956,063/4,901,438
Timothy A. Harkness.......... -- -- 16,500/16,500 272,250/119,625
Timothy A. Harkness18,750/86,250 660,938/2,744,063
Tony M. Lima................. -- -- 0/75,000 0/375,00010,000/70,000 343,750/2,136,250
John S. Senaldi.............. -- -- 9,200/66,800 347,300/2,150,450
Robert J. Murray............. -- -- 46,999/30,000 2,214,389/944,063
Gillian M.K. HumphriesHumphries....... -- -- 33,033/16,300 586,077/155,350
Tony M. Lima -- -- 0/50,000 0/206,250
Robert J. Murray -- -- 36,165/20,834 634,844/291,888

(1) Represents the fair market value of the underlying shares on the last
day of the fiscal year ($21.7539,733/34,600 1,857,962/1,010,163

- ---------------
(1) Represents the fair market value of the underlying shares on the last day of
the fiscal year ($52.00 based on the closing sales price of the Common Stock
as reported on the NASDAQ National Market) less the exercise price of the
options multiplied by the number of shares underlying the option.

REPORT OF THE COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS ON EXECUTIVE
COMPENSATION

The Compensation Committee of the Board of Directors (the "Committee") is
comprised of Messrs. Anderson and Marion and Dr. Waitz, none of whom has been ana
permanent officer or employee of the Company. The Committee is responsible for
establishing the Company's compensation for executive officers.

The goals of the compensation program are to align compensation with
business objectives and performance and to enable the Company to attract, retain
and reward executive officers and other key employees who contribute to the
long-term success of the Company and to motivate them to enhance long-term
stockholder value. To meet these goals, the Committee has adopted a mix of the
compensation elements of salary, bonus and stock options.

Base Salary. The Committee meets at least annually to review and approve
each executive officer's salary for the ensuing year. When reviewing base
salaries, the Committee considers the following factors, in order of importance:
competitive pay practices, individual performance against goals, levels of
responsibility, breadth of knowledge and prior experience. To provide the
Committee with more information for making compensation comparisons, the Company
surveys a group of comparable companies with a capitalization similar to that of
the Company.

Bonus. The bonus program is a discretionary program for executive officers
and other key employees of the Company. The Committee meets in the first quarter
following the year of the awards to be made to determine the amount of the
bonuses. The bonus award depends on the extent to which the Company and
individual performance objectives are achieved. The Company's objectives consist
of operating, strategic and financial goals that are considered to be critical
to the Company's fundamental long-term goal of building stockholder value. For
fiscal 1998,1999, these goals were related to specific increases in revenue,
operating income and earnings per share over the prior years.

Stock Options. The Option Plans maintained by the Company have been
established to provide employees of the Company with an opportunity to share,
along with stockholders of the Company, in the long-term performance of the
Company. Initial grants of stock options are generally made to eligible
employees upon commencement of employment, with additional grants being made to
certain employees periodically or following a significant change in the job
responsibilities, scope or title of such employment. Stock options under the
Options Plans generally vest over a four or five-year period and expire ten
years from the date of grant. The exercise price of such options is usually 100%
of the fair market value of the underlying stock on the date of grant.

13
16

Guidelines for the number of stock options for each participant under the
Option Plans are generally determined by a formula established by the Committee
whereby several factors are applied to the salary and performance level of each

22.

participant and then related to the approximate market price of the stock at the
time of grant. In awarding stock options, the Committee considers individual
performance, overall contribution to the Company, officer retention, the number
of unvested stock options held by the officer and the total number of stock
options to be awarded.

Section 162(m) of the Internal Revenue Code of 1986 limits the Company to a
deduction for federal income tax purposes of up to $1 million of compensation
paid to certain Named Executive Officers in a taxable year. Compensation above
$1 million may be deducted if it is "performance-based compensation." The
Compensation Committee has determined that stock options granted under the
Company's 1995 Plan with an exercise price at least equal to the fair market
value of the Company's common stock on the date of grant shall be treated as
"performance-based compensation" and any compensation recognized by a Named
Executive Officer as a result of the grant of such a stock options is deductible
by the Company.

CEO Compensation. The Committee used the same procedures described above in
setting the annual salary, bonus and stock option awards for the CEO. The grant
of restricted stock to Dr. Keegan was arrived at through arms-length
negotiations in connection with his initial hire as CEO. The CEO's salary is
determined based on comparisons with companies with a capitalization similar to
that of the Company.

Summary. Through the plans described above, a significant portion of the
Company's compensation program for its executive officers (including the CEO) is
contingent upon the individual's and Company's performance, and realization of
benefits by the CEO and the other executive officers is closely linked to
increases in long-term stockholder value. The Company remains committed to this
philosophy of pay for performance, recognizing that the competitive market for
talented executives and the volatility of the Company's business may result in
highly variable compensation during any given annual period.

COMPENSATION COMMITTEE

David L. Anderson
Andre F. Marion
J. Allan Waitz, Ph.D.

COMPENSATION COMMITTEE INTERLOCKS AND INSIDER PARTICIPATION

As noted above, the Compensation Committee is comprised of three
non-employee directors: Messrs. Anderson and Marion and Dr. Waitz. Mr. Marion
served as an interim chief executive officer between October 1997 and March
1998. No member of the Compensation Committee is or was formerly ana permanent
officer or an employee of the Company. No interlocking relationship exists between
the Company's Board of Directors or Compensation Committee and the board of
directors or compensation committee of any other company, nor has such
interlocking relationship existed in the past.

23.14
17

PERFORMANCE MEASUREMENT COMPARISON(1)

The following graph shows total stockholder return of an investment of $100
in cash on December 13, 1995 for (i) the Company's Common Stock, (ii) the Nasdaq
Stock Index and (iii) a peer group index comprised of all public companies using
SIC Code 3826 (Laboratory Analytical Instruments) (the "Peer Group")(2). All
values assume reinvestment of the full amount of all dividends and are
calculated as of December 31 of each year.

[The following descriptive data is supplied in accordance with Rule 304(d) of
Regulation S-T]COMPARE 5-YEAR CUMULATIVE TOTAL RETURN
AMONG MOLECULAR DEVICES CORP.,
NASDAQ MARKET INDEX AND SIC CODE INDEX(3)

MOLECULAR DEVICES ANALYTICAL INSTRUMENTS NASDAQ
----------------- ---------------------- ------

12/13/95 100.00 100.00 100.00
12/29/95 92.31 108.68 99.63
12/31/96 136.81 130.06 123.81
12/31/97 186.81 154.29 151.45
12/31/98 191.21 193.75 213.61
12/31/99 457.14 313.47 376.74

ASSUMED $100 INVESTED ON DECEMBER 13, 1995
ASSUMES DIVIDED REINVESTED
FISCAL YEAR ENDING -------------------------------------------------------
12/13/95 12/29/95 12/31/96 12/31/97 12/31/98
Molecular Devices 100.00 92.31 136.81 186.81 191.21
Analytical Instruments 100.00 108.68 130.06 154.29 193.75
NASDAQ Market Index 100.00 99.63 123.81 151.45 213.61DECEMBER 31, 1999

(1) This Section is not "soliciting material," is not deemed "filed" with the
SEC and is not to be incorporated by reference in any filing of the Company
under the Securities Act or the Exchange Act, whether made before or after
the date hereof and irrespective of any general incorporation language in
any such filing.

(2) Upon written request of a stockholder, the Company will provide a list of
companies comprising the Peer Group.

(3) The cumulative total return on investment (change in year-end stock price
plus reinvested dividends) for the Company, the Nasdaq Stock Index and the
Peer Group, based on December 13, 1995 = 100. In accordance with the rules
of the SEC, the returns of companies comprising the Peer Group are weighted
according to their respective stock market capitalization at the beginning
of each period for which a return is indicated.

CERTAIN TRANSACTIONS

The Company has entered into employment agreements with certain of its
executive officers. See "Employment Agreements."

24.15
18

OTHER MATTERS

The Board of Directors knows of no other matters that will be presented for
consideration at the Annual Meeting. If any other matters are properly brought
before the meeting, it is the intention of the persons named in the accompanying
proxy to vote on such matters in accordance with their best judgment.

By Order of the Board of Directors

/s/ Andrei M. Manoliu

Andrei M. ManoliuJAMES C. KITCH

James C. Kitch
Secretary

April 16,26, 2000

A COPY OF THE COMPANY'S ANNUAL REPORT TO THE SECURITIES AND EXCHANGE
COMMISSION ON FORM 10-K FOR THE FISCAL YEAR ENDED DECEMBER 31, 1999 A copy of the Company's Annual Report to the Securities and Exchange
Commission on Form 10-K for the fiscal year ended December 31, 1998 is available
without charge upon written request to: Corporate Secretary, Molecular Devices
Corporation, 1311 Orleans Drive, Sunnyvale, California 94089.

Appendix A

All references herein to numbers of
shares already take into account and
give effect to the 2-for-3 reverse stock
split effective on December 7, 1995.IS AVAILABLE
WITHOUT CHARGE UPON WRITTEN REQUEST TO: INVESTOR RELATIONS, MOLECULAR DEVICES
CORPORATION, 1995 STOCK OPTION PLAN
ADOPTED OCTOBER 30, 1995
APPROVED BY SHAREHOLDERS ON DECEMBER 12, 1995
AMENDED BY THE BOARD ON ________________, 1999
AS AMENDED BY THE STOCKHOLDERS ON ___________, 1999

1. PURPOSES.

(a) The purpose of the Plan is to provide a means by which selected
Employees and Directors of and Consultants to the Company, and its Affiliates,
may be given an opportunity to purchase stock of the Company.

(b) The Company, by means of the Plan, seeks to retain the services of
persons who are now Employees or Directors of or Consultants to the Company or
its Affiliates, to secure and retain the services of new Employees, Directors
and Consultants, and to provide incentives for such persons to exert maximum
efforts for the success of the Company and its Affiliates.

(c) The Company intends that the Options issued under the Plan shall,
in the discretion of the Board or any Committee to which responsibility for
administration of the Plan has been delegated pursuant to subsection 3(c), be
either Incentive Stock Options or Nonstatutory Stock Options. All Options shall
be separately designated Incentive Stock Options or Nonstatutory Stock Options
at the time of grant, and in such form as issued pursuant to Section 6, and a
separate certificate or certificates will be issued for shares purchased on
exercise of each type of Option.

2. DEFINITIONS.

(a) "Affiliate" means any parent corporation or subsidiary corporation,
whether now or hereafter existing, as those terms are defined in Sections 424(e)
and (f) respectively, of the Code.

(b) "Board" means the Board of Directors of the Company.

(d) "Committee" means a Committee appointed by the Board in accordance
with subsection 3(c) of the Plan.

(e) "Company" means Molecular Devices Corporation.

(f) "Consultant" means any person, including an advisor, engaged by the
Company or an Affiliate to render consulting services and who is compensated for
such services, provided

11311 ORLEANS DRIVE, SUNNYVALE, CALIFORNIA 94089.

16
All references herein to numbers of
shares already take into account and
give effect to the 2-for-3 reverse stock
split effective on December 7, 1995.

that the term "Consultant" shall not include Directors who are paid only a
director's fee by the Company or who are not compensated by the Company for
their services as Directors.

(g) "Continuous Status as an Employee, Director or Consultant" means
the employment or relationship as a Director or Consultant is not interrupted or
terminated. The Board, in its sole discretion, may determine whether Continuous
Status as an Employee, Director or Consultant shall be considered interrupted in
the case of: (i) any leave of absence approved by the Board, including sick
leave, military leave, or any other personal leave; or (ii) transfers between
locations of the Company or between the Company, Affiliates or their successors.

(h) "Covered Employee" means the chief executive officer and the four
(4) other highest compensated officers of the Company for whom total
compensation is required to be reported to shareholders under the Exchange Act,
as determined for purposes of Section 162(m) of the Code.

(i) "Director" means a member of the Board.

(j) "Employee" means any person, including Officers and Directors,
employed by the Company or any Affiliate of the Company. Neither service as a
Director nor payment of a director's fee by the Company shall be sufficient to
constitute "employment" by the Company.

(k) "Exchange Act" means the Securities Exchange Act of 1934, as
amended.

(l) "Fair Market Value" means as of any date, the value of the Common
Stock of the Company determined as follows:

(1) If the common stock is listed on any established stock
exchange or a national market system, including without limitation the National
Market System of the National Association of Securities Dealers, Inc. Automated
Quotation ("NASDAQ") System, the Fair Market Value of a share of common stock
shall be the closing sales price for such stock (or the closing bid, if no sales
were reported) as quoted on such system or exchange (or the exchange with the
greatest volume of trading in common stock) on the last market trading day prior
to the day of determination, as reported in the Wall Street Journal or such
other source as the Board deems reliable;

(2) If the common stock is quoted on the NASDAQ System (but
not on the National Market System thereof) or is regularly quoted by a
recognized securities dealer but selling prices are not reported, the Fair
Market Value of a share of common stock shall be the mean between the bid and
asked prices for the common stock on the last market trading day prior to the
day of determination, as reported in the Wall Street Journal or such other
source as the Board deems reliable;

(3) In the absence of an established market for the common
stock, the Fair Market Value shall be determined in good faith by the Board.

219

1467-PS-00
All references herein to numbers of
shares already take into account and
give effect to the 2-for-3 reverse stock
split effective on December 7, 1995.

(m) "Incentive Stock Option" means an Option intended to qualify as an
incentive stock option within the meaning of Section 422 of the Code and the
regulations promulgated thereunder.

(n) "Non-Employee Director" means a Director of the Company who either
(i) is not a current Employee or Officer of the Company or its parent or a
subsidiary, does not receive compensation (directly or indirectly) from the
Company or its parent or a subsidiary for services rendered as a consultant or
in any capacity other than as a Director (except for an amount as to which
disclosure would not be required under Item 404(a) of Regulation S-K promulgated
pursuant to the Securities Act ("Regulation S-K")), does not possess an interest
in any other transaction as to which disclosure would be required under Item
404(a) of Regulation S-K and is not engaged in a business relationship as to
which disclosure would be required under Item 404(b) of Regulation S-K; or (ii)
is otherwise considered a "non-employee director" for purposes of Rule 16b-3.

(o) "Nonstatutory Stock Option" means an Option not intended to qualify
as an Incentive Stock Option.

(p) "Officer" means a person who is an officer of the Company within
the meaning of Section 16 of the Exchange Act and the rules and regulations
promulgated thereunder.

(q) "Option" means a stock option granted pursuant to the Plan.

(r) "Option Agreement" means a written agreement between the Company
and an Optionee evidencing the terms and conditions of an individual Option
grant. Each Option Agreement shall be subject to the terms and conditions of the
Plan.

(s) "Optionee" means an Employee, Director or Consultant who holds an
outstanding Option.

(t) "Outside Director" means a Director who either (i) is not a current
employee of the Company or an "affiliated corporation" (within the meaning of
the Treasury regulations promulgated under Section 162(m) of the Code), is not a
former employee of the Company or an "affiliated corporation" receiving
compensation for prior services (other than benefits under a tax qualified
pension plan), was not an officer of the Company or an "affiliated corporation"
at any time, and is not currently receiving direct or indirect remuneration from
the Company or an "affiliated corporation" for services in any capacity other
than as a Director, or (ii) is otherwise considered an "outside director" for
purposes of Section 162(m) of the Code.

(u) "Plan" means this Molecular Devices 1995 Stock Option Plan.

(v) "Rule 16b-3" means Rule 16b-3 of the Exchange Act or any successor
to Rule 16b-3, as in effect when discretion is being exercised with respect to
the Plan.

All references herein to numbers of
shares already take into account and
give effect to the 2-for-3 reverse stock
split effective on December 7, 1995.

3. ADMINISTRATION.

(a) The Plan shall be administered by the Board unless and until the
Board delegates administration to a Committee, as provided in subsection 3(c).

(b) The Board shall have the power, subject to, and within the
limitations of, the express provisions of the Plan:

(1) To determine from time to time which of the persons
eligible under the Plan shall be granted Options; when and how each Option shall
be granted; whether an Option will be an Incentive Stock Option or a
Nonstatutory Stock Option; the provisions of each Option granted (which need not
be identical), including the time or times such Option may be exercised in whole
or in part; and the number of shares for which an Option shall be granted to
each such person.

(2) To construe and interpret the Plan and Options granted
under it, and to establish, amend and revoke rules and regulations for its
administration. The Board, in the exercise of this power, may correct any
defect, omission or inconsistency in the Plan or in any Option Agreement, in a
manner and to the extent it shall deem necessary or expedient to make the Plan
fully effective.

(3) To amend the Plan or an Option as provided in Section 11.

(4) Generally, to exercise such powers and to perform such
acts as the Board deems necessary or expedient to promote the best interests of
the Company.

(c) The Board may delegate administration of the Plan to a committee
composed of not fewer than two (2) members (the "Committee"), all of the members
of which Committee shall be Non-Employee Directors and may also be, in the
discretion of the Board, Outside Directors. If administration is delegated to a
Committee, the Committee shall have, in connection with the administration of
the Plan, the powers theretofore possessed by the Board (and references in this
Plan to the Board shall thereafter be to the Committee), subject, however, to
such resolutions, not inconsistent with the provisions of the Plan, as may be
adopted from time to time by the Board. The Board may abolish the Committee at
any time and revest in the Board the administration of the Plan. Notwithstanding
anything in this Section 3 to the contrary, the Board or the Committee may
delegate to a committee of one or more members of the Board the authority to
grant Options to eligible persons who (1) are not then subject to Section 16 of
the Exchange Act and/or (2) are either (i) not then Covered Employees and are
not expected to be Covered Employees at the time of recognition of income
resulting from such Option, or (ii) not persons with respect to whom the Company
wishes to comply with Section 162(m) of the Code.

4. SHARES SUBJECT TO THE PLAN.

(a) Subject to the provisions of Section 10 relating to adjustments
upon changes in stock, the stock that may be sold pursuant to Options shall not
exceed in the aggregate one million seven hundred fifty thousand (1,750,000)
shares of Company common stock, plus up to one million (1,000,000) shares of
Company Common Stock to the extent that such shares

All references herein to numbers of
shares already take into account and
give effect to the 2-for-3 reverse stock
split effective on December 7, 1995.

previously reserved under the Company's terminated 1988 Stock Option Plan (the
"1988 Plan") (i) have not, as of the date of the adoption of this Plan,
previously been issued pursuant to the exercise of options under the 1988 Plan,
and (ii) are not, as of the date of adoption of this Plan, subject to options
outstanding under the 1988 Plan. If any Option granted under the Plan or any
stock option granted under the 1988 Plan shall for any reason expire or
otherwise terminate, in whole or in part, without having been exercised in full,
the stock not acquired shall revert to and again become available for issuance
under this Plan.

(b) The stock subject to the Plan may be unissued shares or reacquired
shares, bought on the market or otherwise.

5. ELIGIBILITY.

(a) Incentive Stock Options may be granted only to Employees.
Nonstatutory Stock Options may be granted only to Employees, Directors or
Consultants.

(b) No person shall be eligible for the grant of an Option if, at the
time of grant, such person owns (or is deemed to own pursuant to Section 424(d)
of the Code) stock possessing more than ten percent (10%) of the total combined
voting power of all classes of stock of the Company or of any of its Affiliates
unless the exercise price of such Option is at least one hundred ten percent
(110%) of the Fair Market Value of such stock at the date of grant and the
Option is not exercisable after the expiration of five (5) years from the date
of grant.

(c) Subject to the provisions of Section 10 relating to adjustments
upon changes in stock, no person shall be eligible to be granted Options
covering more than Five Hundred Thousand (500,000) shares of the Company's
common stock in any calendar year.

6. OPTION PROVISIONS.

Each Option shall be in such form and shall contain such terms and
conditions as the Board shall deem appropriate. The provisions of separate
Options need not be identical, but each Option shall include (through
incorporation of provisions hereof by reference in the Option or otherwise) the
substance of each of the following provisions:

(a) Term. No Option shall be exercisable after the expiration of ten
(10) years from the date it was granted.

(b) Price. The exercise price of each Incentive Stock Option shall be
not less than one hundred percent (100%) of the Fair Market Value of the stock
subject to the Option on the date the Option is granted. The exercise price of
each Nonstatutory Stock Option shall be not less than eighty-five percent (85%)
of the Fair Market Value of the stock subject to the Option on the date the
Option is granted. Notwithstanding the foregoing, an Option (whether and
Incentive Stock Option or Nonstatutory Stock Option) may be granted with an
option exercise price lower than that set forth above if such option is granted
pursuant to an assumption or substitution for another option in a manner
qualifying with the provisions of Section 424(a) of the Code.

All references herein to numbers of
shares already take into account and
give effect to the 2-for-3 reverse stock
split effective on December 7, 1995.

(c) Consideration. The purchase price of stock acquired pursuant to an
Option shall be paid, to the extent permitted by applicable statutes and
regulations, either (i) in cash at the time the Option is exercised, or (ii) at
the discretion of the Board or the Committee, at the time of the grant of the
Option, (A) by delivery to the Company of other common stock of the Company, (B)
according to a deferred payment or other arrangement (which may include, without
limiting the generality of the foregoing, the use of other common stock of the
Company) with the person to whom the Option is granted or to whom the Option is
transferred pursuant to subsection 6(d), or (C) in any other form of legal
consideration that may be acceptable to the Board.

In the case of any deferred payment arrangement, interest shall be
payable at least annually and shall be charged at the minimum rate of interest
necessary to avoid the treatment as interest, under any applicable provisions of
the Code, of any amounts other than amounts stated to be interest under the
deferred payment arrangement.

(d) Transferability. An Option shall not be transferable except by will
or by the laws of descent and distribution, and shall be exercisable during the
lifetime of the person to whom the Option is granted only by such person. A
Nonstatutory Stock Option shall not be transferable except by will or by the
laws of descent and distribution or pursuant to a domestic relations order
satisfying the requirements of Rule 16b-3 and the rules thereunder (a "DRO"),
and shall be exercisable during the lifetime of the person to whom the Option is
granted only by such person or any transferee pursuant to a DRO. The person to
whom the Option is granted may, by delivering written notice to the Company, in
a form satisfactory to the Company, designate a third party who, in the event of
the death of the Optionee, shall thereafter be entitled to exercise the Option.

(e) Vesting. The total number of shares of stock subject to an Option
may, but need not, be allotted in periodic installments (which may, but need
not, be equal). The Option Agreement may provide that from time to time during
each of such installment periods, the Option may become exercisable ("vest")
with respect to some or all of the shares allotted to that period, and may be
exercised with respect to some or all of the shares allotted to such period
and/or any prior period as to which the Option became vested but was not fully
exercised. The Option may be subject to such other terms and conditions on the
time or times when it may be exercised (which may be based on performance or
other criteria) as the Board may deem appropriate. The provisions of this
subsection 6(e) are subject to any Option provisions governing the minimum
number of shares as to which an Option may be exercised.

(f) Securities Law Compliance. The Company may require any Optionee, or
any person to whom an Option is transferred under subsection 6(d), as a
condition of exercising any such Option, (1) to give written assurances
satisfactory to the Company as to the Optionee's knowledge and experience in
financial and business matters and/or to employ a purchaser representative
reasonably satisfactory to the Company who is knowledgeable and experienced in
financial and business matters, and that he or she is capable of evaluating,
alone or together with the purchaser representative, the merits and risks of
exercising the Option; and (2) to give written assurances satisfactory to the
Company stating that such person is acquiring the stock subject to the Option
for such person's own account and not with any present intention of selling or
otherwise distributing the stock. The foregoing requirements, and any assurances
given pursuant

All references herein to numbers of
shares already take into account and
give effect to the 2-for-3 reverse stock
split effective on December 7, 1995.

to such requirements, shall be inoperative if (i) the issuance of the shares
upon the exercise of the Option has been registered under a then currently
effective registration statement under the Securities Act of 1933, as amended
(the "Securities Act"), or (ii) as to any particular requirement, a
determination is made by counsel for the Company that such requirement need not
be met in the circumstances under the then applicable securities laws. The
Company may, upon advice of counsel to the Company, place legends on stock
certificates issued under the Plan as such counsel deems necessary or
appropriate in order to comply with applicable securities laws, including, but
not limited to, legends restricting the transfer of the stock.

(g) Termination of Employment or Relationship as a Director or
Consultant. In the event an Optionee's Continuous Status as an Employee,
Director or Consultant terminates (other than upon the Optionee's death or
disability), the Optionee may exercise his or her Option (to the extent that the
Optionee was entitled to exercise it at the date of termination) but only within
such period of time ending on the earlier of (i) the date three (3) months after
the termination of the Optionee's Continuous Status as an Employee, Director or
Consultant, or such longer or shorter period specified in the Option Agreement,
or (ii) the expiration of the term of the Option as set forth in the Option
Agreement. If, after termination, the Optionee does not exercise his or her
Option within the time specified in the Option Agreement, the Option shall
terminate, and the shares covered by such Option shall revert to and again
become available for issuance under the Plan.

(h) Disability of Optionee. In the event an Optionee's Continuous
Status as an Employee, Director or Consultant terminates as a result of the
Optionee's disability, the Optionee may exercise his or her Option (to the
extent that the Optionee was entitled to exercise it at the date of
termination), but only within such period of time ending on the earlier of (i)
the date twelve (12) months following such termination (or such longer or
shorter period specified in the Option Agreement), or (ii) the expiration of the
term of the Option as set forth in the Option Agreement. If, at the date of
termination, the Optionee is not entitled to exercise his or her entire Option,
the shares covered by the unexercisable portion of the Option shall revert to
and again become available for issuance under the Plan. If, after termination,
the Optionee does not exercise his or her Option within the time specified
herein, the Option shall terminate, and the shares covered by such Option shall
revert to and again become available for issuance under the Plan.

(i) Death of Optionee. In the event of the death of an Optionee during,
or within a period specified in the Option after the termination of, the
Optionee's Continuous Status as an Employee, Director or Consultant, the Option
may be exercised (to the extent the Optionee was entitled to exercise the Option
at the date of death) by the Optionee's estate, by a person who acquired the
right to exercise the Option by bequest or inheritance or by a person designated
to exercise the option upon the Optionee's death pursuant to subsection 6(d),
but only within the period ending on the earlier of (i) the date eighteen (18)
months following the date of death (or such longer or shorter period specified
in the Option Agreement), or (ii) the expiration of the term of such Option as
set forth in the Option Agreement. If, at the time of death, the Optionee was
not entitled to exercise his or her entire Option, the shares covered by the
unexercisable portion of the Option shall revert to and again become available
for issuance under the Plan. If, after death, the Option is not exercised within
the time specified herein, the Option shall

All references herein to numbers of
shares already take into account and
give effect to the 2-for-3 reverse stock
split effective on December 7, 1995.

terminate, and the shares covered by such Option shall revert to and again
become available for issuance under the Plan.

(j) Early Exercise. The Option may, but need not, include a provision
whereby the Optionee may elect at any time while an Employee, Director or
Consultant to exercise the Option as to any part or all of the shares subject to
the Option prior to the full vesting of the Option. Any unvested shares so
purchased may be subject to a repurchase right in favor of the Company or to any
other restriction the Board determines to be appropriate.

(k) Withholding. To the extent provided by the terms of an Option
Agreement, the Optionee may satisfy any federal, state or local tax withholding
obligation relating to the exercise of such Option by any of the following means
or by a combination of such means: (1) tendering a cash payment; (2) authorizing
the Company to withhold shares from the shares of the common stock otherwise
issuable to the Optionee as a result of the exercise of the Option; or (3)
delivering to the Company owned and unencumbered shares of the common stock of
the Company.

7. COVENANTS OF THE COMPANY.

(a) During the terms of the Options, the Company shall keep available
at all times the number of shares of stock required to satisfy such Options.

(b) The Company shall seek to obtain from each regulatory commission or
agency having jurisdiction over the Plan such authority as may be required to
issue and sell shares of stock upon exercise of the Options; provided, however,
that this undertaking shall not require the Company to register under the
Securities Act either the Plan, any Option or any stock issued or issuable
pursuant to any such Option. If, after reasonable efforts, the Company is unable
to obtain from any such regulatory commission or agency the authority which
counsel for the Company deems necessary for the lawful issuance and sale of
stock under the Plan, the Company shall be relieved from any liability for
failure to issue and sell stock upon exercise of such Options unless and until
such authority is obtained.

8. USE OF PROCEEDS FROM STOCK.

Proceeds from the sale of stock pursuant to Options shall constitute
general funds of the Company.

9. MISCELLANEOUS.

(a) The Board shall have the power to accelerate the time at which an
Option may first be exercised or the time during which an Option or any part
thereof will vest pursuant to subsection 6(e), notwithstanding the provisions in
the Option stating the time at which it may first be exercised or the time
during which it will vest.

(b) Neither an Optionee nor any person to whom an Option is transferred
under subsection 6(d) shall be deemed to be the holder of, or to have any of the
rights of a holder with

All references herein to numbers of
shares already take into account and
give effect to the 2-for-3 reverse stock
split effective on December 7, 1995.

respect to, any shares subject to such Option unless and until such person has
satisfied all requirements for exercise of the Option pursuant to its terms.

(c) Nothing in the Plan or any instrument executed or Option granted
pursuant thereto shall confer upon any Employee, Director, Consultant or
Optionee any right to continue in the employ of the Company or any Affiliate (or
to continue acting as a Director or Consultant) or shall affect the right of the
Company or any Affiliate to terminate the employment or relationship as a
Director or Consultant of any Employee, Director, Consultant or Optionee with or
without cause.

(d) To the extent that the aggregate Fair Market Value (determined at
the time of grant) of stock with respect to which Incentive Stock Options
granted after 1986 are exercisable for the first time by any Optionee during any
calendar year under all plans of the Company and its Affiliates exceeds one
hundred thousand dollars ($100,000), the Options or portions thereof which
exceed such limit (according to the order in which they were granted) shall be
treated as Nonstatutory Stock Options.

(e) (1) The Board or the Committee shall have the authority to effect,
at any time and from time to time (i) the repricing of any outstanding Options
under the Plan and/or (ii) with the consent of the affected holders of Options,
the cancellation of any outstanding Options and the grant in substitution
therefor of new Options under the Plan covering the same or different numbers of
shares of Common Stock, but having an exercise price per share not less than
eighty-five percent (85%) of the Fair Market Value (one hundred percent (100%)
of the Fair Market Value in the case of an Incentive Stock Option or, in the
case of a ten percent (10%) stockholder (as defined in subsection 5(b)), not
less than one hundred and ten percent (110%) of the Fair Market Value) per share
of Common Stock on the new grant date.

(2) Shares subject to an Option canceled under this subsection 9(e)
shall continue to be counted against the maximum award of Options permitted to
be granted pursuant to subsection 5(c) of the Plan. The repricing of an Option
under this subsection 9(e), resulting in a reduction of the exercise price,
shall be deemed to be a cancellation of the original Option and the grant of a
substitute Option; in the event of such repricing, both the original and the
substituted Options shall be counted against the maximum awards of Options
permitted to be granted pursuant to subsection 5(c) of the Plan. The provisions
of this subsection 9(e) shall be applicable only to the extent required by
Section 162(m) of the Code.

10. ADJUSTMENTS UPON CHANGES IN STOCK.

(a) If any change is made in the stock subject to the Plan, or subject
to any Option (through merger, consolidation, reorganization, recapitalization,
stock dividend, dividend in property other than cash, stock split, liquidating
dividend, combination of shares, exchange of shares, change in corporate
structure or otherwise), the Plan will be appropriately adjusted in the types of
securities and maximum number of shares subject to the Plan pursuant to
subsection 4(a) and the maximum number of shares subject to award to any person
during any calendar year pursuant to subsection 5(c), and the outstanding
Options will be appropriately adjusted in the

All references herein to numbers of
shares already take into account and
give effect to the 2-for-3 reverse stock
split effective on December 7, 1995.

types of securities and number of shares and price per share of stock subject to
such outstanding Options.

(b) In the event of: (1) a dissolution, liquidation or sale of
substantially all of the assets of the Company; (2) a merger or consolidation in
which the Company is not the surviving corporation; or (3) a reverse merger in
which the Company is the surviving corporation but the shares of the Company's
common stock outstanding immediately preceding the merger are converted by
virtue of the merger into other property, whether in the form of securities,
cash or otherwise, then to the extent permitted by applicable law: (i) any
surviving corporation shall assume any Options outstanding under the Plan or
shall substitute similar Options for those outstanding under the Plan, or (ii)
such Options shall continue in full force and effect. In the event any surviving
corporation refuses to assume or continue such Options, or to substitute similar
options for those outstanding under the Plan, then, with respect to Options held
by persons then performing services as Employees, Directors or Consultants, then
such Options shall be terminated if not exercised prior to such event; provided,
however, that the time during which such Options may be exercised may, at the
discretion of the Board of Directors, be accelerated and the Options terminated
if not exercised prior to such event.

11. AMENDMENT OF THE PLAN AND OPTIONS.

(a) The Board at any time, and from time to time, may amend the Plan.
However, except as provided in Section 10 relating to adjustments upon changes
in stock, no amendment shall be effective unless approved by the stockholders of
the Company within twelve (12) months before or after the adoption of the
amendment, where the amendment will:

(1) Increase the number of shares reserved for Options under the
Plan;

(2) Modify the requirements as to eligibility for participation in
the Plan (to the extent such modification requires stockholder approval in order
for the Plan to satisfy the requirements of Section 422 of the Code or any
Nasdaq or securities exchange listing requirements); or

(3) Modify the Plan in any other way if such modification requires
stockholder approval in order for the Plan to satisfy the requirements of
Section 422 of the Code or to comply with the requirements of Rule 16b-3, or any
Nasdaq or securities exchange listing requirements.

(b) The Board may in its sole discretion submit any other amendment to
the Plan for stockholder approval, including, but not limited to, amendments to
the Plan intended to satisfy the requirements of Section 162(m) of the Code and
the regulations promulgated thereunder regarding the exclusion of
performance-based compensation from the limit on corporate deductibility of
compensation paid to certain executive officers.

(c) It is expressly contemplated that the Board may amend the Plan in
any respect the Board deems necessary or advisable to provide Optionees with the
maximum benefits provided or to be provided under the provisions of the Code and
the regulations promulgated thereunder

All references herein to numbers of
shares already take into account and
give effect to the 2-for-3 reverse stock
split effective on December 7, 1995.

relating to Incentive Stock Options and/or to bring the Plan and/or Incentive
Stock Options granted under it into compliance therewith.

(d) Rights and obligations under any Option granted before amendment of
the Plan shall not be impaired by any amendment of the Plan unless (i) the
Company requests the consent of the person to whom the Option was granted and
(ii) such person consents in writing.

(e) The Board at any time, and from time to time, may amend the terms
of any one or more Options; provided, however, that the rights and obligations
under any Option shall not be impaired by any such amendment unless (i) the
Company requests the consent of the person to whom the Option was granted and
(ii) such person consents in writing.

12. TERMINATION OR SUSPENSION OF THE PLAN.

(a) The Board may suspend or terminate the Plan at any time. Unless
sooner terminated, the Plan shall terminate on October 29, 2005, which shall be
within ten (10) years from the date the Plan is adopted by the Board or approved
by the stockholders of the Company, whichever is earlier. No Options may be
granted under the Plan while the Plan is suspended or after it is terminated.

(b) Rights and obligations under any Option granted while the Plan is
in effect shall not be impaired by suspension or termination of the Plan, except
with the consent of the person to whom the Option was granted.

13. EFFECTIVE DATE OF PLAN.

The Plan shall become effective as determined by the Board, but no
Options granted under the Plan shall be exercised unless and until the Plan has
been approved by the stockholders of the Company, which approval shall be within
twelve (12) months before or after the date the Plan is adopted by the Board,
and, if required, an appropriate permit has been issued by the Commissioner of
Corporations of the State of California.

Appendix B

MOLECULAR DEVICES CORPORATION
1995 NON-EMPLOYEE DIRECTORS' STOCK OPTION PLANADOPTED ON
SEPTEMBER 13, 1995
APPROVED BY SHAREHOLDERS
ON DECEMBER 12, 1995
AMENDED BY THE BOARD ON JANUARY 29, 1999
AS AMENDED BY THE STOCKHOLDERS ON ___________, 1999

1. PURPOSE.

(a) The purpose of the 1995 Non-Employee Directors' Stock Option Plan
(the "Plan") is to provide a means by which each director of MOLECULAR DEVICES
CORPORATION (the "Company") who is not otherwise an employee of the Company or
of any Affiliate of the Company (each such person being hereafter referred to as
a "Non-Employee Director") will be given an opportunity to purchase stock of the
Company.

(b) The word "Affiliate" as used in the Plan means any parent
corporation or subsidiary corporation of the Company as those terms are defined
in Sections 424(e) and (f), respectively, of the Internal Revenue Code of 1986,
as amended from time to time (the "Code").

(c) The Company, by means of the Plan, seeks to retain the services of
persons now serving as Non-Employee Directors of the Company, to secure and
retain the services of persons capable of serving in such capacity, and to
provide incentives for such persons to exert maximum efforts for the success of
the Company.

2. ADMINISTRATION.

(a) The Plan shall be administered by the Board of Directors of the
Company (the "Board") unless and until the Board delegates administration to a
committee, as provided in subparagraph 2(b).

(b) The Board may delegate administration of the Plan to a committee
composed of not fewer than two (2) members of the Board (the "Committee"). If
administration is delegated to a Committee, the Committee shall have, in
connection with the administration of the Plan, the powers theretofore possessed
by the Board, subject, however, to such resolutions, not inconsistent with the
provisions of the Plan, as may be adopted from time to time by the Board. If the
Committee is delegated authority to amend or fix the timing or terms of options
granted under the Plan, then the composition of the Committee shall comply with
the requirements for exemption of option grants from the application of Section
16 of the Securities Exchange Act of 1934, or the terms of such options shall be
such as to qualify such options for such exemption. The Board may abolish the
Committee at any time and revest in the Board the administration of the Plan.

3. SHARES SUBJECT TO THE PLAN.

(a) Subject to the provisions of paragraph 10 relating to adjustments
upon changes in stock, the stock that may be sold pursuant to options granted
under the Plan shall not exceed in the aggregate three hundred forty-seven
thousand five hundred (347,500) shares of the Company's common stock. If any
option granted under the Plan shall for any reason expire or otherwise terminate
without having been exercised in full, the stock not purchased under such option
shall again become available for the Plan.

(b) The stock subject to the Plan may be unissued shares or reacquired
shares, bought on the market or otherwise.

4. ELIGIBILITY.

(a) Options shall be granted only to Non-Employee Directors of the
Company.

5. NON-DISCRETIONARY GRANTS.

(a) Upon the date of the initial approval of the Plan by the Board (the
"Adoption Date"), each person who is then a Non-Employee Director automatically
shall be granted an option to purchase sixteen thousand five hundred (16,500)
shares of common stock of the Company on the terms and conditions set forth
herein.

(b) Each person who is, after the Adoption Date, elected for the first
time to be a Non-Employee Director automatically shall, upon the date of his
initial election to be a Non-Employee Director by the Board or shareholders of
the Company, be granted an option to purchase ten thousand (10,000) shares of
common stock of the Company on the terms and conditions set forth herein.

(c) Following the Adoption Date, each Non-Employee Director shall
automatically be granted an additional Option to purchase four thousand (4,000)
shares of common stock of the Company on the terms and conditions set forth
herein immediately following each annual meeting of stockholders.

(d) Notwithstanding anything to the contrary set forth in this Section
5, each Non-Employee Director who received a stock option grant pursuant to this
Plan in September 1998 (a "September 1998 Grant") shall not be entitled to
future grants under this Plan until the September 1998 Grant shall have fully
vested. On the date that the September 1998 Grant shall have fully vested, such
Non-Employee Director shall be treated as having been initially elected to be a
Non-Employee Director on such date and receive the stock option referenced in
Section 5(b) and, thereafter, shall be eligible to receive the stock options
referenced in Section 5(c).

6. OPTION PROVISIONS.

Each option shall be subject to the following terms and conditions:

(a) The term of each option commences on the date it is granted and,
unless sooner terminated as set forth herein, expires on the date ("Expiration
Date") ten (10) years from the

date of grant. If the optionee's service as a Non-Employee Director or employee
of or consultant to the Company or any Affiliate terminates for any reason or
for no reason, the option shall terminate on the earlier of the Expiration Date
or the date three (3) months following the date of termination of all such
service; provided, however, that if such termination of service is due to the
optionee's death, the option shall terminate on the earlier of the Expiration
Date or eighteen (18) months following the date of the optionee's death. In any
and all circumstances, an option may be exercised following termination of the
optionee's service as a Non-Employee Director or employee of or consultant to
the Company or any Affiliate only as to that number of shares as to which it was
exercisable on the date of termination of such all service under the provisions
of subparagraph 6(e).

(b) Subject to subparagraph 4(b), the exercise price of each option
shall be one hundred percent (100%) of the fair market value of the stock
subject to such option on the date such option is granted.

(c) Payment of the exercise price of each option is due in full in cash
upon any exercise when the number of shares being purchased upon such exercise
is less than 1,000 shares; but when the number of shares being purchased upon an
exercise is 1,000 or more shares, the optionee may elect to make payment of the
exercise price under one of the following alternatives:

(i) Payment of the exercise price per share in cash at the time of

exercise; or

(ii) Provided that at the time of the exercise the Company's common
stock is publicly traded and quoted regularly in the Wall Street Journal,
payment by delivery of shares of common stock of the Company already owned by
the optionee, held for the period required to avoid a charge to the Company's
reported earnings, and owned free and clear of any liens, claims, encumbrances
or security interest, which common stock shall be valued at its fair market
value on the date preceding the date of exercise; or

(iii) Payment by a combination of the methods of payment specified
in subparagraph 6(c)(i) and 6(c)(ii) above.

Notwithstanding the foregoing, this option may be exercised pursuant to
a program developed under Regulation T as promulgated by the Federal Reserve
Board which results in the receipt of cash (or check) by the Company prior to
the issuance of shares of the Company's common stock.

(d) An option shall not be transferable except by will or by the laws
of descent and distribution, or pursuant to a domestic relations order
satisfying the requirements of Rule 16a-12 under the Securities Exchange Act of
1934 (a "DRO") and shall be exercisable during the lifetime of the person to
whom the option is granted only by such person (or by his guardian or legal
representative) or transferee pursuant to a DRO. Notwithstanding the foregoing,
the optionee may, by delivering written notice to the Company in a form
satisfactory to the Company, designate a third party who, in the event of the
death of the optionee, shall thereafter be entitled to exercise the option.

(e) The option shall become exercisable in installments over a period
of four years from the date of grant in equal annual installments commencing on
the date one year after the date of grant of the option, provided that the
optionee has, during the entire period prior to such vesting date, continuously
served as a Non-Employee Director or employee of or consultant to the Company or
any Affiliate of the Company, whereupon such option shall become fully
exercisable in accordance with its terms with respect to that portion of the
shares represented by that installment. For purposes of vesting under this
subparagraph 6(e), attendance at no less than two-thirds (2/3) of the Board
meetings occurring during an installment period is required in order for an
optionee serving as a Non-Employee Director to vest for such installment;
failure to satisfy this requirement during any particular installment period
shall result in an abatement of the vesting of the option during the applicable
installment period and the aggregate vesting period of such option shall be
increased by one additional year.

(f) The Company may require any optionee, or any person to whom an
option is transferred under subparagraph 6(d), as a condition of exercising any
such option: (i) to give written assurances satisfactory to the Company as to
the optionee's knowledge and experience in financial and business matters; and
(ii) to give written assurances satisfactory to the Company stating that such
person is acquiring the stock subject to the option for such person's own
account and not with any present intention of selling or otherwise distributing
the stock. These requirements, and any assurances given pursuant to such
requirements, shall be inoperative if (i) the issuance of the shares upon the
exercise of the option has been registered under a then-currently-effective
registration statement under the Securities Act of 1933, as amended (the
"Securities Act"), or (ii), as to any particular requirement, a determination is
made by counsel for the Company that such requirement need not be met in the
circumstances under the then-applicable securities laws.

(g) Notwithstanding anything to the contrary contained herein, an
option may not be exercised unless the shares issuable upon exercise of such
option are then registered under the Securities Act or, if such shares are not
then so registered, the Company has determined that such exercise and issuance
would be exempt from the registration requirements of the Securities Act.

7. COVENANTS OF THE COMPANY.

(a) During the terms of the options granted under the Plan, the Company
shall keep available at all times the number of shares of stock required to
satisfy such options.

(b) The Company shall seek to obtain from each regulatory commission or
agency having jurisdiction over the Plan such authority as may be required to
issue and sell shares of stock upon exercise of the options granted under the
Plan; provided, however, that this undertaking shall not require the Company to
register under the Securities Act either the Plan, any option granted under the
Plan, or any stock issued or issuable pursuant to any such option. If, after
reasonable efforts, the Company is unable to obtain from any such regulatory
commission or agency the authority which counsel for the Company deems necessary
for the lawful issuance and sale of stock under the Plan, the Company shall be
relieved from any liability for failure to issue and sell stock upon exercise of
such options.

8. USE OF PROCEEDS FROM STOCK.

Proceeds from the sale of stock pursuant to options granted under the
Plan shall constitute general funds of the Company.

9. MISCELLANEOUS.

(a) Neither an optionee nor any person to whom an option is transferred
under subparagraph 6(d) shall be deemed to be the holder of, or to have any of
the rights of a holder with respect to, any shares subject to such option unless
and until such person has satisfied all requirements for exercise of the option
pursuant to its terms.

(b) Nothing in the Plan or in any instrument executed pursuant thereto
shall confer upon any Non-Employee Director any right to continue in the service
of the Company or any Affiliate or shall affect any right of the Company, its
Board or stockholders or any Affiliate to terminate the service of any
Non-Employee Director with or without cause.

(c) No Non-Employee Director, individually or as a member of a group,
and no beneficiary or other person claiming under or through him, shall have any
right, title or interest in or to any option reserved for the purposes of the
Plan except as to such shares of common stock, if any, as shall have been
reserved for him pursuant to an option granted to him.

(d) In connection with each option made pursuant to the Plan, it shall
be a condition precedent to the Company's obligation to issue or transfer shares
to a Non-Employee Director, or to evidence the removal of any restrictions on
transfer, that such Non-Employee Director make arrangements satisfactory to the
Company to insure that the amount of any federal or other withholding tax
required to be withheld with respect to such sale or transfer, or such removal
or lapse, is made available to the Company for timely payment of such tax.

(i) If the common stock is listed on any established stock exchange
or a national market system, including without limitation the National Market
System of the National Association of Securities Dealers, Inc. Automated
Quotation ("Nasdaq") System, the Fair Market Value of a share of common stock
shall be the closing sales price for such stock (or the closing bid, if no sales
were reported) as quoted on such system or exchange (or the exchange with the
greatest volume of trading in common stock) on the last market trading day prior
to the day of determination, as reporting in the Wall Street Journal or such
other source as the Board deems reliable;

(ii) If the common stock is quoted on the Nasdaq System (but not on
the National Market System thereof) or is regularly quoted by a recognized
securities dealer but selling prices are not reported, the Fair Market Value of
a share of common stock shall be the mean between the bid and asked prices for
the common stock on the last market trading day prior to the day of
determination, as reported in the Wall Street Journal or such other source as
the Board deems reliable;

(iii) In the absence of an established market for the common stock,
the Fair Market Value shall be determined in good faith by the Board.

10. ADJUSTMENTS UPON CHANGES IN STOCK.

(a) If any change is made in the stock subject to the Plan, or subject
to any option granted under the Plan (through merger, consolidation,
reorganization, recapitalization, stock dividend, dividend in property other
than cash, stock split, liquidating dividend, combination of shares, exchange of
shares, change in corporate structure or otherwise), the Plan and outstanding
options will be appropriately adjusted in the class(es) and maximum number of
shares subject to the Plan and the class(es) and number of shares and price per
share of stock subject to outstanding options.

(b) In the event of: (1) a merger or consolidation in which the Company
is not the surviving corporation; (2) a reverse merger in which the Company is
the surviving corporation but the shares of the Company's common stock
outstanding immediately preceding the merger are converted by virtue of the
merger into other property, whether in the form of securities, cash or
otherwise; or (3) any other capital reorganization in which more than fifty
percent (50%) of the shares of the Company entitled to vote are exchanged, the
time during which options outstanding under the Plan may be exercised shall be
accelerated and the options terminated if not exercised prior to such event.

11. AMENDMENT OF THE PLAN.

(a) The Board at any time, and from time to time, may amend the Plan,
provided, however, that except as provided in paragraph 10 relating to
adjustments upon changes in stock, no amendment shall be effective unless
approved by the stockholders of the Company within twelve (12) months before or
after the adoption of the amendment, where the amendment will:

(i) Increase the number of shares which may be issued under the
Plan;

(ii) Modify the requirements as to eligibility for participation in
the Plan (to the extent such modification requires stockholder approval in order
for the Plan to comply with the requirements of Rule 16b-3); or

(iii) Modify the Plan in any other way if such modification
requires stockholder approval in order for the Plan to comply with the
requirements of Nasdaq or any securities exchange on which the Company desires
prices for its common stock to be quoted.

(b) Rights and obligations under any option granted before any
amendment of the Plan shall not be impaired by such amendment unless (i) the
Company requests the consent of the person to whom the option was granted and
(ii) such person consents in writing.

12. TERMINATION OR SUSPENSION OF THE PLAN.

(a) The Board may suspend or terminate the Plan at any time. No options
may be granted under the Plan while the Plan is suspended or after it is
terminated.

(b) Rights and obligations under any option granted while the Plan is
in effect shall not be impaired by suspension or termination of the Plan, except
with the consent of the person to whom the option was granted.

13. EFFECTIVE DATE OF PLAN; CONDITIONS OF EXERCISE.

(a) The Plan shall become effective upon adoption by the Board of
Directors, subject to the condition subsequent that the Plan is approved by the
stockholders of the Company.

(b) No option granted under the Plan shall be exercised or exercisable
unless and until the condition of subparagraph 13(a) above has been met.

Appendix C20

DETACH HERE

PROXY

MOLECULAR DEVICES CORPORATION

PROXY SOLICITED BY THE BOARD OF DIRECTORS
FOR THE ANNUAL MEETING OF STOCKHOLDERS
TO BE HELD ON MAY 20, 199925, 2000

The undersigned hereby appoints Joseph D. Keegan, Ph.D., and Timothy A.
Harkness, and each of them, as attorneys and proxies of the undersigned, with
full power of substitution, to vote all of the shares of stock of Molecular Devices
Corporation which the undersigned may be entitled to vote at the Annual Meeting
of Stockholders of Molecular Devices Corporation to be held at the Company's
corporate headquarters, located at 1311 Orleans Drive, Sunnyvale, California
94089 on Thursday, May 20, 199925, 2000 at 10:30 a.m., local time, and at any and all
postponements, continuations and adjournments thereof, with all powers that the
undersigned would possess if personally present, upon and in respect of the
following matters and in accordance with the following instructions, with
discretionary authority as to any and all other matters that may properly come
before the meeting.

UNLESS A CONTRARY DIRECTION IS INDICATED, THIS PROXY WILL BE VOTED FOR ALL
NOMINEES LISTED IN PROPOSAL 1 AND FOR PROPOSALSPROPOSAL 2, 3 AND 4, AS MORE SPECIFICALLY DESCRIBED
IN THE PROXY STATEMENT. IF SPECIFIC INSTRUCTIONS ARE INDICATED, THIS PROXY WILL
BE VOTED IN ACCORDANCE THEREWITH.

- ----------- -----------
SEE REVERSE SEE REVERSE
SIDE CONTINUED AND TO BE SIGNED ON REVERSE SIDE SIDE
- ----------- -----------
21

DETACH HERE

PLEASE MARK
[ ] VOTES AS IN
EXAMPLE.

MANAGEMENT RECOMMENDS A VOTE FOR THE NOMINEES FOR DIRECTOR LISTED BELOW.

PROPOSAL 1:BELOW:

Proposal 1. To elect directors to hold office until the next Annual Meeting of
Stockholders and until their successors are elected.

[ ] For all nominees listed below [ ] WITHHOLD Authority
(except as marked to the contrary to vote for all nominees
below). listed below.

Nominees:NOMINEES: Joseph D. Keegan, Ph.D., Moshe H. Alafi, David L. Anderson,
A. Blaine Bowman, Paul Goddard, Ph.D., Andre F. Marion,
Harden M. McConnell, Ph.D., J. Allan Waitz,Waltz, Ph.D.

FOR ALL NOMINEES [ ] [ ] WITHHOLD
LISTED ABOVE (EXCEPT AUTHORITY TO VOTE
AS MARKED TO THE FOR ALL NOMINEES
CONTRARY) LISTED ABOVE

[ ]
-----------------------------------------------------------------------------
To withhold authority to vote for any nominee(s), write such nominee(s)'
name(s) below:

- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------above.

MANAGEMENT RECOMMENDS A VOTE
FOR PROPOSALS 2, 3 AND 4.

PROPOSAL 2: To approve amendments to the Company's 1995 Stock Option Plan (i)
to increase the aggregate number of shares of Common Stock
authorized for issuance under such plan by 1,000,000 shares, and
(ii) to make certain technical amendments to the plan.

[ ]2.

FOR [ ] AGAINST [ ] ABSTAIN
(Continued on other side)

(Continued from other side)

PROPOSAL 3: To approve amendments to the Company's 1995 Non-Employee
Directors' Stock Option Plan (i) to increase the aggregate number
of shares of Common Stock authorized for issuance under such plan
by 100,000 shares, (ii) to revise the timing, vesting and number
of shares subject to grants to be issued to non-employee
directors, and (iii) to make certain technical amendments to the
plan.

[ ] FOR [ ] AGAINST [ ] ABSTAIN

PROPOSAL 4:2. To ratify the selection of Ernst & Young LLP as [ ] [ ] [ ]
independent auditors of the Company for its fiscal
year ending December 31, 1999.

[ ] FOR [ ] AGAINST [ ] ABSTAIN

DATED _________________ __________________________________________

__________________________________________
SIGNATURE(S)2000.

Please sign exactly as your name appears
hereon. If the stock is registered in
the names of two or more persons, each
should sign. Executors, administrators,
trustees, guardians and attorneys-in-factattorney-in-fact
should add their titles. If signer is a
corporation, please give full corporate
name and have a duly authorized officer
sign, stating title. If signer is a
partnership, please sign in partnership
name by authorized person.

Please vote, date and promptly return this proxy in the enclosed return envelope
which is postage prepaid if mailed in the United States.

2.
PLEASE VOTE, DATE AND PROMPTLY RETURN
THIS PROXY IN THE ENCLOSED RETURN
ENVELOPE WHICH IS POSTAGE PREPAID IF
MAILED IN THE UNITED STATES.

Signature: Date:
-------------------------------------------- --------------------